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Abstract

Obesity is rapidly increasing in prevalence, and has become one of the
leading contributors to poor health in the world. Increased body weight by necessity
must be a result of increased nutrient intake relative to total energy expenditure.
While many have focused on the importance of caloric consumption in determining
weight, it is increasingly clear that differences in energy expenditure, basal metabolic
rates and/or adaptive thermogenesis are also important variables that contribute to
human obesity.
The experiments in this thesis start off by demonstrating that a significant
portion of leptin-mediated weight loss is the result of an increase in energy
expenditure caused by the hormone. They then go on to take a closer look at three
candidate organs in which such changes in caloric expenditure are likely to be
occurring. Our study finds that leptin treatment of ob/ob mice reduces the basal
metabolic rate, uncoupled respiration (i.e. leak), and non-mitochondrial respiration of
primary hepatocytes. We show that this is due to changes in the substrate oxidation
system in liver mitochondria as well as changes in mitochondrial structure, and
volume density. These changes are directly caused by leptin, and are not downstream
of the hormone’s correction of hepatic steatosis.
We next explored the proteomic and lipidomic modifications underlying the
changes discussed above. Leptin-mediated changes in three components of the
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mitochondrial respiratory chain can account for the aforementioned metabolic effects
of the hormone in the liver. Dramatic alterations in levels of the enzyme ELOVL5
might be responsible for the hepatic steatosis exhibited with leptin deficiency, and for
its correction with leptin treatment. Furthermore, differences in mitochondrial
cardiolipin levels may also be associated with the observed leptin-mediated changes
in the liver. Finally, we show a trend that leptin may be altering the levels of reactive
oxygen species in hepatic mitochondria.
Having completed a thorough investigation into leptin-mediated changes in
the liver, we moved on to the other two candidate organs, the heart and skeletal
muscle. Our results show that leptin clearly modulates mitochondrial respiration in
these tissues, though we cannot yet say exactly how it does so. In conclusion, this
thesis illustrates the effects of leptin levels on the liver, and details the mechanisms
by which the hormone induces change down to the proteomic level. It also shows
clear leptin-mediated effects in skeletal muscle and the heart, and sets the stage for
further investigation into the role of these tissues in leptin induced weight loss.
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Chapter 1: Introduction
Obesity as a Global Health Problem
Defining Obesity and the Associated Physical and Psychological Stress
Obesity is loosely defined as an excess amount of body fat relative to lean
body mass. The most commonly used method for categorizing individuals as being
overweight or obese is body mass index (BMI), which is calculated by dividing one’s
weight in kilograms by the square of his/her height in meters. Waist circumference,
skin fold thickness, and bioimpedance are other methods used in defining obesity.
The World Health Organization defines individuals with BMIs over 25 as being
overweight, and those with a BMI over 30 as obese (Committee, 1995; W.H.O.,
1997).
Obese individuals are at a higher risk for developing coronary heart disease,
type 2 diabetes mellitus, hypertension, cancer, strokes, sleep apnea, cholelithiasis, and
osteoarthritis (Bennett, 1996; Kopelman, 2000). Studies have shown a positive
correlation between mortality and body weight, with the lowest mortality being found
in those who are slightly underweight (Lew, 1985). Both the prospective Nurses
Health Study (Manson et al., 1995), which included approximately 115,000 women,
and a 26-year follow-up of over 5,000 patients in the Framingham Heart Study
(Hubert et al., 1983) showed an increased risk of mortality as BMI increases.
Similarly, the American Cancer Society’s Cancer Prevention Study found that a
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higher BMI is associated
with

greater

(Stevens

et

mortality
al.,

1998).

Indeed, individuals with a
BMI of 19 to 24.9 are at a
20% increased risk of death,
which increases to 30% for a
BMI over 25, 60% for a
BMI over 27, and exceeds
110% for a BMI over 29
(Figure 1.1) (Calle et al.,
1999).
In

addition

to

incurring a higher risk of
mortality, obese individuals
are constantly subjected to social pressure as well as societal stigma, and thus face a
tremendous pyscosocial burden (Friedman, 2003). Obese people often have a poor
self image and impaired social skills, both of which are exacerbated by societal
discrimination against the obese (Bennett, 1996; Crocker et al., 1993; Friedman,
2000). Overweight individuals are more likely to be categorized as having negative
personality traits and thought of as being unhappy (Hiller, 1981). Furthermore,
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studies have demonstrated that the obese are victims of prejudice and discriminatory
behavior that negatively affects their education, employment, health care, and
economic status (Bennett, 1996; Puhl and Brownell, 2001; Sarlio-Lahteenkorva et al.,
1995). As a result of this stigmatization, obese individuals are subject to
psychological distress, poor self-esteem, and sometimes worsening weight problems
(Myers and Rosen, 1999).
Increasing Prevalence of Obesity
Obesity is rapidly emerging as a significant global health problem, and has
joined the ranks of malnutrition and infectious disease as a leading contributor to poor
health in the world (Kopelman, 2000). The most recent National Health and Nutrition
Examination Survey (NHANES) indicates that 66% of adults in the US are either
overweight or obese, a cohort that has been growing over the last fourty years (Ogden
et al., 2006). Obese individuals made up 32.2% of the US adult population in 2004, as
compared to 12.8% in 1962 (Kuczmarski et al., 1994). This trend manifests itself in
younger individuals as well, and has shown an even more alarming rate of increase in
children and adolescents. As a matter of fact, the prevalence of overweight children in
the US has more than doubled since 1976 (Troiano et al., 1995; Yanovski and
Yanovski, 2002). Since the presence of obesity in early infancy, childhood, and
adolescence markedly increases the risk for obesity in adulthood, these youngsters are
often predisposed to a lifetime of health problems (Dietz, 1994).
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Though obesity is often viewed as a problem only encountered in countries of
affluence, it is actually rapidly increasing in the developing world (Taubes, 1998). In
fact, it is estimated that the number of obese people in the world is equivalent to those
suffering from hunger (Campbell, 2000). Obesity has also taken a hold in countries
such as Japan, Korea, China, and Thailand - nations where it has traditionally not
been a concern (Popkin, 1994). Similar trends in obesity have been observed
throughout Europe as well, though they are reported to be less severe (W.H.O., 1988).
On the other hand, obesity rates amongst Pacific Islanders are astonishingly high,
with a prevalence of over 60% in certain populations (Hodge et al., 1995; Shmulewitz
et al., 2001).
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When discussing trends in the prevalence of obesity, we must keep in mind
that the disorder is defined as a threshold (i.e. BMI > 30), and thus relatively small
increases in average weight can have a disproportionate effect on its incidence
(Friedman, 2003). For example, while the incidence of obesity in the US increased by
one third from 1991 to 2000 (i.e. 23.3% to 30.9%), the average weight of a typical
American rose by approximately 7 to 10 pounds (Flegal and Troiano, 2000).
Therefore, an increase in the average BMI of the US population from 26.7 to 28.1,
lead to a marked increase in people with a BMI > 30, and hence the sharp rise in
obese individuals (Figure 1.4) (Friedman, 2003).

7

Nature vs. Nurture, A Closer Look at the Causes of Obesity
Environmental Contributions to Obesity
Billions of dollars are generated in revenue every year by the diet industry,
with over 30% of adults in the United States reporting that they are trying to loose
weight (Friedman, 2000; Serdula et al., 1999). A fundamental concept presented in
the marketing of many diets is the idea that adjustments to body weight are simply a
matter of determination. The common oversimplification that obesity results solely
from a lack of willpower, gluttony, and utter laziness has in recent years been
challenged by a wealth of scientific knowledge. Clinical and molecular studies have
shed light on the interplay between genes and the environment in leading to the
disorder of energy imbalance, and it has become quite clear that both factors play a
determining role when it comes to an individual’s body weight.
The environment can be looked upon as contributing to the development of
obesity in whichever ways it increases the frequency of behaviors that promote
positive energy balance (Hill and Peters, 1998). In today’s society, the availability of
food, popularity of high calorie meals and drinks, and increased portion size, have all
contributed to the increased prevalence of obesity. Even with the call to alarm against
trends in weight gain, foods low in fats or carbohydrates, but high in calories, have
been marketed as smart and guilt-free alternatives.
Alongside this increase in caloric intake over recent history, modernization
has brought with it a decrease in physical activity. Studies have shown that children
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spend an increased amount of leisure time watching television or playing video
games, which may be contributing to the observed increase in childhood obesity
(Robinson, 2001). This makes sense, as reduced physical activity and low energy
expenditure are risk factors for weight gain (Ravussin et al., 1988a; Rissanen et al.,
1991).
Since the human genome has not changed significantly in the last 20 years
(Hill and Peters, 1998), much of the blame for the increase in obesity can be placed
on environmental factors. This hypothesis is reinforced by studies of migrant
populations, one of which shows that the likelihood of an Asian American individual
being overweight or obese increases with the number of years he/she has spent in the
US (Lauderdale and Rathouz, 2000). Another such study shows that obesity is more
prevalent amongst American-born versus foreign-born individuals, and increases
greatly in second and third generation immigrants (Popkin and Udry, 1998).
The Genetic Influence Over Obesity
In addition to the environmental contributions to body weight, there is a
precise physiological mechanism rooted in genetics that exerts control over energy
balance. Obesity genes code for the molecular components that regulate the
homeostasis between energetic inputs and outputs, a system that precisely matches
caloric consumption with caloric expenditure to maintain controlled stores of energy,
mainly in the form of fat (Spiegelman and Flier, 2001; Zhang et al., 1994).
Exemplifying this is the fact that a typical human being consumes approximately 10
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million calories over the course of a decade, with generally only a modest change in
body weight (Friedman, 2003). Calculations show that this trend requires food intake
and energy expenditure to match one another within 0.17% (Weigle, 1994), a level of
precision that exceeds the ability of nutritionists to count calories by several orders of
magnitude. The ‘set point’ hypothesis buds from this inherent stability in body
weight, and proposes that food intake and energy expenditure are coordinated to keep
body weight relatively constant (Friedman and Leibel, 1992; Harris, 1990). In support
of this theory, when a study restricted food intake to reduce body weight by 10%, it
found that energy expenditure decreased to offset the attempted changes (Leibel et al.,
1995).
If such a precise homeostatic mechanism for the regulation of body weight
exists, then why has average body weight, and thus obesity, climbed so drastically
over the last few decades? Shouldn’t this physiological system resist changes in
weight due to the abundance of calories or sedentary lifestyle that has become so
pervasive in modern day society? To answer these questions, we can turn to the
“thrifty gene hypothesis”. This theory says that genes which allowed for the effective
storage of energy as adipose tissue when food was scarce, as was the case in ancient
hunter-gatherer societies, provided an adaptive advantage and were selected for over
time (Neel, 1999). Thus, individuals that were able to store energy to use during times
of food deprivation were able to survive longer and pass on the genes that allowed
them to do so to a larger fraction of the next generation. The relatively sudden change
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in environment that has made access to calorie dense food commonplace, has in the
context of thousands of years of selection for “thrifty genes” made obesity a serious
health problem.
If the change in environment has provided the bricks with which the house of
obesity has been built, then genetic factors are the foundation holding it up. As much
as 80% of the variance seen in BMI amongst individuals is attributable to differences
in genetic makeup (Rosenbaum et al., 1997). An individual’s genes govern his/her
control over positive energy balance and defense system against developing obesity
in a particular environment (Hill and Peters, 1998). Studies of adopted children, twins
reared together or apart, and patterns of familial aggregation have all supported the
importance of genetic factors in the determination of BMI. A study of over 100,000
people from either biological or adoptive relationships found a BMI correlation of
0.70 in monozygotic twins and 0.32 in dizygotic twins, which represents a heritability
of 50-90% (Maes et al., 1997). This high heritability is equivalent to that of height
and far exceeds that of many disorders generally considered to have a genetic basis
(Allison et al., 1996).
Additional studies show that identical twins that have been reared apart have
only a slightly lower correlation in BMI than those that have been raised together, and
a shared childhood environment does not affect the similarity of their BMI later in life
(Stunkard et al., 1990). On the flip side of the coin, adoptees raised together do not
exhibit any correlation between BMIs (Stunkard et al., 1986). Furthermore, the rate
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and proportion of weight gain, as well as the site of fat deposition, are all more
closely linked in within pairs of identical twins than between them (Bouchard et al.,
1990). This effect is also seen in mice, where genetically distinct inbred strains show
very different amounts of weight gain in response to a high fat diet (West et al., 1992;
West et al., 1994). A hypothesis that accounts for both the genetic foundation of
obesity as well as the environmental contribution to it, proposes that susceptibility to
obesity is under genetic control and that behavior and environment determine the
phenotypic expression of inherited susceptibility genes (Barsh et al., 2000).
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Body Energy Homeostasis
The Balance Between Energy Intake and Expenditure
Obesity, defined medically as a state of increased body weight to the extent
that produces adverse health consequences, is a disease of energy imbalance. When
energy intake exceeds energy expenditure, the excess calories are stored as fat. If this
state of positive energy balance continues over time, so will weight gain that
eventually leads to obesity. Assuming that an individual has no problems with the
absorption of nutrients, energy intake will be directly proportional to the calories that
he/she consumes.
Energy expenditure, on
the other hand, is a bit more
complex, and represents the
conversion of oxygen and an
energy

source

(fats,

carbohydrates, and proteins) to
carbon dioxide, water, heat
and work on the environment
(Lowell

and

Spiegelman,

2000). It takes the form of
physical
metabolism,

activity,
and

basal
adaptive
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thermogenesis – which refers to energy dissipated in the form of heat in response to a
change in the environment, such as cold exposure or diet alterations (Figure 1.3)
(Lowell and Spiegelman, 2000). Basal metabolic rate (BMR) refers to the numerous
biochemical processes required to sustain life, and is traditionally defined as the
minimal caloric requirement for an organism to maintain life in the absence of
external stimulation, work and growth (Harper et al., 2001a). There are many
physiological processes that continue in an organism at this state, including blood
circulation and respiration. The reactions that contribute to BMR on a cellular level
include protein turnover, ion cycling across the plasma membrane, turnover of
nucleic acids and lipids, and proton flux across the mitochondrial inner membrane
(Brand, 1990; Hulbert and Else, 2000).
It is important to realize that a process can only cause or prevent obesity if it
affects the overall energy equation of an organism (Spiegelman and Flier, 2001). An
example of deviation from this understanding is the thought that limiting adipose
tissue development can rectify obesity and its complications. However, experiments
in which fat cell differentiation, development, and survival have been diminished
show that this is not the case. Instead of producing healthy and obesity resistant
organisms, these studies created mice that suffered from the lack of an appropriate
depot in which to deposit excess energy, and exhibited a loss of critical adipocyte
derived hormones (Ross et al., 1993; Shimomura et al., 1998). As a result, these mice
had increased levels of blood lipids, fatty livers and diabetes, the combination of
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which lead to death. Along these lines, when a genetically altered mouse is found to
be leaner, one can conclude that an alteration has taken place in the total energy
balance scheme – usually involving food intake or energy expenditure (Spiegelman
and Flier, 2001).
Central Regulation of Energy Balance
The central nervous system (CNS) regulates energy balance, and thus body
weight, through its effects on behavior (i.e. feeding and physical activity), the
autonomic nervous system (regulation of energy expenditure and other aspects of
metabolism), and the neuroendocrine system (i.e. growth hormone, thyroid hormone,
cortisol, insulin, and sex steroids). The effectiveness of this system is highlighted by
data showing that many species forced to gain weight by overfeeding, or lose weight
by food restriction, will return to their control body weight levels upon return to
voluntary food intake (Harris, 1990; Kandel et al., 2000).
The location of such a CNS energy regulation system was implicated through
observations that animals with lesions in the hypothalamus demonstrated
dysregulation of body weight and had excess fat mass (Harris, 1990; Hetherington
and Ranson, 1942). Further studies showed that different regions of the hypothalamus
have distinct contributions to energy regulation. Lesions of the lateral hypothalamus
result in increased energy expenditure and decreased food intake, which work in
concert to decrease body fat mass. Conversely, lesions in the ventromedial
hypothalamus result in hyperphagia and obesity (Hetherington and Ranson, 1942;
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Powley and Keesey, 1970). Thus, through these experiments it was hypothesized that
the lateral hypothalamus was the feeding center of the brain, while the ventromedial
hypothalamus was the satiety center. The identification of leptin as the signal which
indicated lipid energy stores to these centers was crucial in uncovering how they
maintain body weight homeostasis, and is discussed in the next section.
Short and Long Term Regulation of Energy Intake
The decision to begin and end feeding involves the integration of a number of
factors, including food availability, metabolic status, hormone levels, and neural
signaling – including visual, olfactory, emotional, and cognitive inputs (Schwartz et
al., 2000b). The factors regulating food intake can be divided between short-term
signals, which involve the initiation and termination of meals, and long-term signals,
which promote regulation of caloric stores and energy homeostasis. Induction of
satiety is the major determinant of meal size, and is the result of neural and endocrine
inputs, such as gut distention and the release of cholecystokinin (CCK) (Moran,
2000). Regulation at the level of individual meal size is insufficient to account for
energy homeostasis over longer periods of time, as mice repeatedly injected with
CCK retain weight by ingesting a larger number of small meals (Spiegelman and
Flier, 2001). Therefore, long-term signals that reflect the status of energy stores, such
as the fat derived hormone leptin, are required to maintain energy balance.
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Discovery of Leptin and its Receptor
A Circulating Signal of Energy Stores
Support for a circulating factor in the blood as the afferent signal of energy
stores was popularized by the observation that transferring the blood of an obese
animal with a lesion in the ventromedial hypothalamus into a lean animal caused the
later to decrease food intake and lose body fat (Hervey, 1959). Kennedy had also
proposed a “lipostatic theory”, in which the hypothalamus responded to an adipose
secreted “satiety factor” that circulated in the blood. He postulated that such a factor
should

have

characteristics:

three
it

defining

should

be

produced by adipose tissue, it
should circulate in the plasma,
and it should be proportional to
fat mass (Kennedy, 1953).
Further support for such
a circulating signal of satiety
came from Coleman’s parabiosis
experiments,

in

which

the

circulations of two mice were
fused. In these studies, when a
wild-type and ob/ob mouse were
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fused, the ob/ob mouse decreased its food intake and lost weight, indicating that there
is a circulating factor that the ob/ob mouse lacks (Figure 1.4, bottom panel). This
factor is also present in the db/db mouse, which when fused with an ob/ob can make
it loose weight as well (Figure 1.4, middle panel). The fusion of a db/db mouse with a
wild-type mouse resulted in death of the wild-type mouse by self imposed starvation
and no significant changes in the db/db animal, suggesting that the obesity seen in
db/db mice may be the result of resistance to this factor (Figure 1.4, top panel).
Positional Cloning of the ob Gene, and Identification of Leptin
Kennedy’s proposed “satiety factor” was discovered with the positional
cloning of the ob gene, which was found to have high expressivity in adipose tissue
(Zhang et al., 1994). The protein product of this gene was named leptin, from the
Greek word leptos, meaning thin. Leptin fulfils all the requirements set by Kennedy
for his factor: it is produced primarily by adipose tissue in nonpregnant animals
(Zhang et al., 1994), it is a 16 kilodalton circulating member of the long-chain helical
cytokine family (Zhang et al., 1997), and it is highly correlated with BMI in humans
(Maffei et al., 1995).
Leptin conveys satiety by functioning as the afferent signal in a negative
feedback loop regulating adipose tissue mass. When one is at his/her stable weight,
the amount of leptin in circulation maintains body energy homeostasis by eliciting a
state where food intake equals energy expenditure (Figure 1.5, top panel) (Friedman,
2000). A decrease in fat reserves reduces the amount of circulating leptin, which
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signals

to

the

hypothalamus to increase
food intake and decrease
energy

expenditure

(Figure

1.5,

panel).

second

Conversely,

increased

fat

reserves

raise circulating levels of
leptin, which triggers the
hypothalamus

to

cut

back food intake and increase energy expenditure (Figure 1.5, third panel). In most
obese individuals there is a decreased sensitivity to leptin, and thus even at higher
circulating levels of the hormone, they maintain body energy homeostasis by
balancing food intake with energy expenditure (Figure 1.5, bottom panel).
Mouse Models to Study the Function of Leptin
The ob knockout mouse model that lead to the identification of leptin can also
be used to study the hormone. There are two such mutant strains of mice that are
unable to produce leptin. The more commonly used ob1j mutant has a nonsense
mutation in the leptin gene, which results in a truncated protein that is not secreted
into circulation (Zhang et al., 1994). The levels of ob RNA are elevated in the
adipocytes of this mutant, suggesting that leptin expression may be under feedback
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regulation. In the ob2j mutant, on the other hand, the first intron of the gene has an Etn
transposon inserted into it. This generates hybrid RNAs where the splice donor of the
non-coding first exon is joined with the splice acceptor of the transposon, which
prevents the formation of mature RNA (Moon and Friedman, 1997).
The defect in the production of leptin in these ob mice leads to animals that
are hyperphagic and hypometabolic, rendering them obese from a very young age. In
addition to being obese, ob/ob animals are diabetic, hypothermic, sterile, and show
decreased immune function (Coleman, 1978). These mice behave very much like
animals that have been starved, since in the absence of leptin their bodies are under
the perception of being in extreme negative energy balance. Thus the functions less
critical for short-term survival in a nutritionally deficient state, such as reproductive
capability, are forgone to conserve as much energy as possible.
Restoration of physiological levels of leptin by intraperitoneal injection or
subcutaneous infusion of the hormone in ob/ob mice leads to a dose-dependent
decrease in body weight and food intake, corrects the metabolic defects discussed
above, and restores fertility (Campfield et al., 1995; Halaas et al., 1995;
Pelleymounter et al., 1995). Furthermore, leptin treatment of these mice improves
their hyperglycemia, hyperinsulinemia, and hypercorticosteronemia (Pelleymounter et
al., 1995; Stephens et al., 1995). It is interesting to note that the reduction in body
weight resulting from leptin treatment is specifically due to the depletion of adipose
tissue and does not involve any changes in lean body mass (Halaas et al., 1995). In
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support of this observation, adenovirus-mediated leptin gene therapy specifically
depletes fat mass as well (Chen et al., 1996a).
The Leptin Receptor
Another monogenic mutation inherited in an autosomal recessive fashion,
which also left animals obese and diabetic, was described alongside ob (Coleman,
1978). Mice with this mutation were called db, for diabetic, and the protein product of
this gene was later shown to code for the leptin receptor Ob-R (Chen et al., 1996b;
Tartaglia et al., 1995). Ob-R is a receptor that spans the plasma membrane, and has
five alternatively spliced variants (Chen et al., 1996b; Chua et al., 1996; Lee et al.,
1996). The C57Bl/Ks strain of db mice has an insert that leads to an alternatively
spliced transcript containing a premature stop codon, which inhibits the expression of
Ob-Rb. Other isoforms of the Ob receptor, however, are not affected by this mutation
and remain intact (Chen et al., 1996b; Lee et al., 1996). The fact that C57Bl/Ks mice
exhibit the same phenotype as animals unable to make any of the Ob-R isoforms
suggests that Ob-Rb is the receptor splice variant that is critical in detecting leptin
levels. In other studies, leptin had no effect on STAT or JAK activation in cells that
only expressed Ob-Ra, providing further support for the importance of Ob-Rb
(Ghilardi and Skoda, 1997; Ghilardi et al., 1996).
This long form of the ob receptor, Ob-Rb, is the only splice variant with an
intracellular domain capable of transducing signals. When leptin binds to this
receptor, the later is phosphorylated on at least two intracellular tyrosine residues,
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namely Tyr985 and Tyr1138 (Li and Friedman, 1999). The phosphorylation of
Tyr1138 is followed by the phosphorylation of JAK-2 and STAT-3, which leads to
suppressor of cytokine signaling (SOCS)-3 transcription (Banks et al., 2000). Along
these lines, cells transfected with the mutant receptor found in db/db mice showed
defective STAT signaling (Ghilardi et al., 1996). Furthermore, leptin injection leads
to a dose-dependent activation of STAT-3 in the hypothalamus of wild-type and
ob/ob mice, but not db/db mice (Vaisse et al., 1996). Finally, leptin induces the
expression of the STAT-3 target gene fos in the hypothalamus (Woods and Stock,
1996).
Once SOCS-3 transcription has been activated, Tyr985 comes into play, as it
is needed in the negative regulation of the leptin receptor by SOCS-3 (Bjorbak et al.,
2000). Peripheral administration of leptin has been shown to up-regulate
hypothalamic levels of SOCS-3 mRNA (Bjorbaek et al., 1998). SOCS proteins
negatively feedback on receptor signaling in response to cytokine stimulation, and
levels of SOCS-3 remain up regulated for 20 hours after leptin administration,
indicating long-term effects. Furthermore, SOCS-3 is over expressed in the
hypothalamus of Ay obese mice, and its over expression in cell culture leads to
inhibition of Ob-Rb signaling. These observations suggest that SOCS-3 may be
involved in leptin’s role in resisting obesity (Bjorbaek et al., 1999; Bjorbaek et al.,
1998).
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In addition to playing a role in the negative regulation of the leptin receptor,
Tyr985 leads to docking and phosphorylation of the SH2 domain containing protein
tyrosine phosphatase (SHP)-2 (Carpenter et al., 1998; Li and Friedman, 1999). SHP-2
decreases Jak2 phosphorylation, and thus blunts leptin signal transduction (Carpenter
et al., 1998; Li and Friedman, 1999). Protein-tyrosine phosphatase, PTP1B, also
decreases Jak2 phosphorylation, and thus mice lacking the former have increased
levels of phosphorylated STAT-3, and are resistant to obesity (Cheng et al., 2002;
Cook and Unger, 2002; Elchebly et al., 1999; Zabolothy et al., 2002). The full
significance of these signaling cascades remains to be demonstrated in vivo, and a
deeper understanding of them may be valuable in comprehending physiological
disturbances resulting in obesity.
Ob-Rb has been detected in T cells, lymph nodes, the jejunum and vascular
endothelium, however its highest expression seems to be in hypothalamic neurons
(Chen et al., 1996b; Ghilardi et al., 1996; Lord, 1998; Morton et al., 1998). In situ
hybridization studies have shown the receptor to be located in the arcuate nucleus,
paraventricular nucleus (PVN), dorsomedial hypothalamic nucleus (DMH),
ventromedial hypothalamic nucleus (VMH), and lateral hypothalamus (LH) – brain
regions known to be involved in regulating appetite and body weight (Elmquist et al.,
1997; Elmquist et al., 1998; Fei et al., 1997; Hetherington and Ranson, 1942; Mercer
et al., 1996).
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Currently, a definitive role for the other isoforms of Ob-R remains to be
established. Ob-Ra and Ob-Rc are expressed on the microvasculature of the brain,
and it has been suggested that they may be involved in leptin transport across the
blood brain barrier (Banks et al., 1996; Hileman et al., 2002). Another splice variant,
Ob-Re, is a soluble isform of the receptor, which appears to bind leptin in the plasma
and assist in its action (Huang et al., 2001; Li et al., 1998).
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Leptin’s Role in Body Weight Regulation
Central vs. Peripheral Mechanisms of Action
The hypothalamus is the master regulator of energy balance in the brain, and
is a major center of integration for leptin signaling. Ob-Rb is highly expressed in the
hypothalamus and rats with lesions in this brain region exhibit leptin resistance,
indicating that leptin has direct effects on the brain (Satoh et al., 1997). Intra-cerebroventricular (I.C.V) injection of leptin reduces food intake, increases energy
expenditure, and results in weight loss (Campfield et al., 1995). Furthermore, leptin
administered at extremely low doses by this means elicits the same weight loss and
anorectic effects as much higher doses given peripherally (Halaas et al., 1997;
Stephens et al., 1995). Administered peripherally, a leptin dose of 200ng/hr in ob/ob
mice and 500ng/hr in wt mice is required for complete depletion of adipose tissue,
and even higher levels are required when the hormone is given as twice daily
injections (Halaas et al., 1995). On the contrary, chronic I.C.V. injection of just 3
ng/hr produces the same effects without increasing circulating leptin levels (Halaas et
al., 1997). Furthermore, leptin rapidly induces STAT-3 DNA binding in the
hypothalamus in a dose dependant manner, an effect that is not seen in any other
tested tissues (Vaisse et al., 1996). Leptin administered either peripherally or centrally
does not induce STAT-3 or cause weight loss in db/db mice (Halaas et al., 1995;
Vaisse et al., 1996). Finally, brain specific expression of leptin receptors in receptor
deficient mice can reverse many aspects of leptin deficiency (Kowalski et al., 2001).
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As a whole, these data strongly suggest that leptin’s actions are mediated in a large
part through the hypothalamus.
It is important to keep in mind, however, that the leptin receptor is broadly
expressed and leptin does have some direct effects on peripheral tissues. For example,
leptin can influence the immune system, angiogenesis, and bone metabolism (Ducy et
al., 2000; Lord, 1998; Sierra-Honigmann et al., 1998). More specifically, leptin has
been reported to have effects on immune cells, muscle, liver, fat, heart, pancreatic βcells, and other cell types (Kim et al., 2000; Lord, 1998; Minokoshi et al., 2002;
O'Rourke et al., 2001; Shimabukuro et al., 1997). Interestingly, both neural pathways
and direct actions in the periphery mediate leptin’s activation of AMP kinase in
peripheral tissues, which plays a role in regulating the oxidation of lipids (Minokoshi
et al., 2002). That being said, the weight reducing effects of leptin which are the main
focus of this thesis, are in large part mediated by the hypothalamus as discussed
above.
The Leptin Regulated Melanocortin Pathway
Targeted deletions and positional cloning of genes, functional neuroanatomy,
and identification of mutant genes in human obesity have all made it possible to gain
insight into the complex central circuits that regulate energy balance. Though there
are a number of brain centers that express leptin receptors and respond to the
hormone, the best characterized and most clinically relevant of these help comprise
the leptin-regulated melanocortin circuit. Seven unique proteins have been shown to
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contribute to weight regulation and obesity in the major components of this circuit,
which are detailed in Figure 1.6 (Spiegelman and Flier, 2001). In this circuit, leptin
acts on two distinct populations of neurons in the arcuate nucleus, namely
NPY/AgRP cells and POMC/CART cells. NPY and AgRP are orexigenic
neuropeptides, and leptin action reduces their expression (Elias et al., 1999; Elmquist
et al., 1999b; Schwartz et al., 2000b). POMC and CART, on the other hand, are
anorexigenic neuropeptides, and leptin action induces their expression (Elias et al.,
1999; Elmquist et al., 1999b; Schwartz et al., 2000b). Therefore, leptin signaling in
the arcuate nucleus through Ob-Rb receptors suppresses two orexigenic peptides and
induces two anorexigenic peptides.
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These neuropeptides then go on to influence second order targets in the
hypothalamus. POMC neurons produce αMSH, which stimulates MC4R receptors
found in the brain and reduces food intake. On the other hand, AgRP works to inhibit
MC4R receptors, which increases feeding and diminishes the hypophagic response to
leptin (Cone, 1999; Fan et al., 1997). Transgenic and pharmacologic experiments
have shown that the dominant obesity syndrome exhibited by the Ay mouse is due to
ectopic expression of the agouti protein that produces obesity by antagonizing the
action of αMSH on MCR4 receptors in the brain (Fan et al., 1997; Graham et al.,
1997; Lu et al., 1994; Ollmann et al., 1997). The action of agouti in these mice
mimics that of AgRP, which is its hypothalamic homolog.
Mice with one copy of the MC4R gene knocked out display moderate obesity,
and those with a homozygous deletion of the receptor are fully obese (Huszar et al.,
1997). In humans, approximate 4-5% of severe obesity is due to mutation at this
location. The disorder in these individuals seems to arise due to haploinsufficiency
rather than a dominant negative mechanism (Farooqi et al., 2000). These findings
highlight the importance of the melanocortin pathway in maintaining normal energy
balance, and suggest that it is extremely tightly regulated (Spiegelman and Flier,
2001).
The melanocortin pathway is also involved in a number of other human and
murine causes of obesity. One such example, which leads to obesity in both
organisms, occurs due to a mutation in the POMC gene that prevents the synthesis of
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αMSH (Krude et al., 1998). Other such mutations that function through POMC
processing occur in the enzymes PC-1 and CPE, and cause obesity in humans and
mice respectively (Barsh et al., 2000). Obesity in mice also results from the targeted
deletion of the MC3R gene, which codes for receptors closely related to MC4R
(Butler et al., 2000). Since the obesity observed with MC3R deletions occurs without
the hyperphagia seen in deletions of MC4R, it is thought that they are involved in
distinct physiological pathways. Melanocortin systems, along with serotonin
pathways, may also be involved in cachexia and eating disorders such as anorexia
nervosa (Marks et al., 2001).
Leptin and the Melanin Concentrating Hormone Circuit
Lesion studies have implicated the lateral hypothalamus and zona incerta as
“feeding centers” of
the brain. Melanin
concentrating
hormone

(MCH),

another hypothalamic
peptide involved in
weight regulation, is
exclusively
expressed

in

large

neurons whose cell
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bodies reside in these areas (Flier, 2004a)(Figure 1.7). Research has also confirmed a
connection between arcuate neurons expressing AGRP/NPY and POMC/CART, and
neurons in the lateral hypothalamus expressing MCH (Elias et al., 1999). Overexpression of MCH in the brain results in obesity and increased susceptibility to a
high fat diet (Ludwig, 2002). Conversely, deletion of the MCH gene produces a
mouse that is lean as the result of hypophagia and increased energy expenditure
(Shimada et al., 1998). Knocking out this gene also substantially suppresses many
aspects of the ob/ob phenotype (Segal-Lieberman et al., 2003).
The MCH receptor, MCHR1, is a G protein coupled receptor that is expressed
widely in the brain. Targeted deletion of this receptor produces a mouse that is lean
due to increased energy expenditure rather than reduced caloric intake (Marsh et al.,
2002). Antagonists to the MCHR1 receptor suppress food intake and resist the obesity
that develops in mice fed a palatable diet (Borowsky et al., 2002).
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Obesity, Energy Expenditure, and the Role of Leptin
Energy Expenditure is Defective in Obesity
There are many lines of support for defects in energy expenditure underlying
obesity, the strongest of which come from monogenic rodent models such as ob/ob,
db/db, and melanocortin-4 receptor gene knock out mice (Lowell and Bachman,
2003). In all three of these genetic models, when food intake is restricted to that of
wild-type controls, marked obesity still develops (Coleman, 1978). Furthermore,
animals in which hypothalamic lesions are induced also become obese when food
restricted to sham-treated control levels (Bray and York, 1979). Indeed, there are a
few exceptions to the rule that animal models of obesity, whether generated through
genetic manipulation or induced through lesions, have decreased energy expenditure
(Lowell and Bachman, 2003). Studies also suggest that obesity in humans is caused at
least in part by reduced energy expenditure. For example, low energy expenditure,
normalized for lean body mass, has been shown to be predictive of future weight gain
(Ravussin et al., 1988a). Thus comprehending the role of energy expenditure in
obesity is critical to understanding the disorder and devising therapies to combat it.
Standard Metabolic Rate
As discussed earlier, basal metabolic rate (BMR) represents the minimal
calories required for an organism to maintain the basic functions of life in the absence
of external stimulation, work and growth. BMR and resting metabolic rate (RMR) are
difficult and not suitable to measure in animals, and thus standard metabolic rate
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(SMR) is used instead (Harper et al., 2001b). SMR is defined as the amount energy
expenditure for an adult organism that is awake but resting, not digesting food, and is
at thermoneutrality – the environmental temperature at which no energy has to be
expended to maintain body temperature (Lowell and Spiegelman, 2000). There is a
large spectrum of varying SMRs across phyla, and endotherms have a five fold
greater metabolic rate than ectotherms of the same size (Rolfe and Brown, 1997).
Furthermore, SMR within a phylum is inversely correlated with body size (Porter and
Brand, 1993). The differences in SMR that exist amongst phyla and species suggest
the presence of regulatory mechanisms that may be manipulated pharmacologically to
change energy balance and increase adaptive thermogenesis (Harper et al., 2001b).
Factors Affecting Adaptive Thermogenesis
Standard metabolic rate and other such measurements represent the
conversion of an energy source (food or stored) and oxygen to carbon dioxide, water,
heat and work on the environment. The presence of heat in the equation above
highlights the fact that many reactions in energy metabolism, such as those that
consume ATP or are catalyzed by the mitochondrial respiratory chain, are exothermic
in nature. Adaptive thermogenesis is defined as heat production in response to
environmental temperature or diet (Lowell and Spiegelman, 2000). This component
of energy expenditure serves to protect an organism from cold exposure or changes in
energy homeostasis after modifications in diet.
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The environmental temperature can greatly influence energy expenditure in an
organism, as highlighted by the fact that oxygen consumption increases by
approximately 2-4 fold in rodents after both acute and chronic incubation at 4oC
(Davis et al., 1960; Depocas et al., 1956). Shivering plays a role in maintaining body
heat in the initial response to this temperature, however with adaptation it disappears
and other mechanisms, including adaptive thermogenesis, take over (Davis et al.,
1960; Foster and Frydman, 1979). Though the effect seen in humans is smaller,
changes in environmental temperature show a similar influence over adaptive
thermogenesis. For example in identically clothed humans, a reduction in ambient
temperature from 28oC to 22oC causes a 7% increase in heat production (Dauncey,
1981).
Food intake also wields influence over adaptive thermogenesis. For example,
starvation can decrease resting metabolic rate by up to 40% (Blaxter, 1989). Along
these lines, adhering to a diet that is able to maintain a 10% reduction in body weight
is associated with decreased energy expenditure (Leibel et al., 1995). The value of
such a regulatory mechanism is clear for times in which the availability of caloric
sources may be scarce, however it serves to counter voluntary weight loss as a result
of dieting. In the face of this reduced energy expenditure, one must maintain a
disproportionately low caloric intake to maintain weight loss – a feat that makes
successful dieting incredibly difficult and leads to the failure of most diets over time
(Friedman, 2003).
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Feeding has the opposite effect on adaptive thermogenesis, and in both
rodents and humans can increase energy expenditure acutely and in the long term.
Acutely, feeding can raise metabolic rate by 25-40%, which is referred to as the
thermic effect of food (Shibata and Bukowiecki, 1987; Sims and Danforth, 1987).
Increased caloric intake over a prolonged period of time can also increase energy
expenditure, which protects against the development of obesity (Levine et al., 1999).
Interestingly, this adaptive response to overfeeding is influenced by genetics
(Bouchard et al., 1990), and varying genetic backgrounds could leave individuals
differently prone to developing obesity.
Central Control of Adaptive Thermogenesis and the Role of Leptin
As was mentioned earlier in our discussion of the hypothalamic influence over
energy homoeostasis, destruction of neurons in the hypothalamus results in obesity
(Elmquist et al., 1999b). The obesity in these cases is usually associated with
increased caloric intake, however even if food is restricted to the level of control
animals, obesity still develops (Himms-Hagen, 1989). Furthermore, mutations in
leptin and its receptor, MCR4, and MCH all influence both food intake and energy
expenditure in a concerted way to influence fat storage (Spiegelman and Flier, 2001).
These findings, along with others, suggest that the hypothalamus has the capacity to
control adaptive thermogenesis (Lowell and Spiegelman, 2000).
There are several lines of evidence suggesting that the sympathetic nervous
system is the main efferent pathway through which the hypothalamus exerts its
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control over adaptive thermogenesis (Lowell and Bachman, 2003). First of all, cold
exposure and diet increase sympathetic nerve activity (Landsberg et al., 1984).
Secondly, exogenous administration of epinephrine and norepinephrine, both in vivo
and in vitro, stimulates energy expenditure. Thirdly, brown adipose tissue is highly
innervated by sympathetic nerves, and the thermogenic activity of it is completely
dependent on intact sympathetic stimulation (Himms-Hagen, 1989). Our current
understanding of diet-induced thermogenesis is summarized in figure 1.8 (Lowell and
Bachman, 2003). As shown in the figure, diet and leptin act on the hypothalamus and
regulate sympathetic nerve activity to increase energy expenditure in different tissues.
While much focus has been directed on the importance of leptin’s role in the
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control of food intake, it is increasingly clear that differences in energy expenditure,
basal metabolic rates and/or adaptive thermogenesis, are also important variables that
contribute to human obesity (Bouchard et al., 1990; Levine et al., 1999; Ravussin,
1995). This is because in addition to reducing caloric intake, leptin infusion of ob/ob
mice increases total energy expenditure, selectively promotes fat metabolism, and
prevents the fall in adaptive thermogenesis that normally occurs with reduced caloric
intake (Doring et al., 1998; Halaas et al., 1997; Hwa et al., 1997; Kamohara et al.,
1997; Mistry et al., 1997; Pelleymounter et al., 1995; Scarpace et al., 1997; van Dijk
et al., 1999). By adjusting for changes in physical activity, it has been shown that
leptin infusion doubles the amount of feeding related adaptive thermogenesis by
acting on both the amplitude and duration of it, and decreases postprandial RQ
(Ruffin and Nicolaidis, 2000). This conclusion is consistent with the finding that
stimulation of the ventromedial hypothalamus (VMH), a brain center through which
leptin exerts some of its catabolic effects as discussed earlier, increases metabolism
and decreases RQ (Ruffin and Nicolaidis, 1999), while lesions in this area cause
obesity (Elmquist et al., 1999b). Therefore, a significant portion of leptin-mediated
weight loss can be attributed to an increase in energy expenditure, including adaptive
thermogenesis, through the pathway outlined in figure 1.8.
Target Tissues Mediating Leptin Driven Adaptive Thermogenesis
While the activation of adaptive thermogenesis in brown adipose tissue by
sympathetic nerve signaling via β-adrenergic receptors and cyclic AMP is well
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established, the induction of skeletal muscle and other tissues by this mechanism
remains to be studied in more detail (Lowell and Spiegelman, 2000). Support for
similar control over these tissues comes from observations that catecholamine
infusion into skeletal muscle increases energy expenditure without the performance of
work (Simonsen et al., 1992). Furthermore, knockout mice unable to produce
catecholamines show greater sensitivity to cold than do mice mutated in UCP-1
(Enerback et al., 1997; Thomas and Palmiter, 1997). These studies suggest that
pathways outside of brown adipose tissue are important contributors to adaptive
thermogenesis.
While leptin’s effects on energy expenditure can be easily demonstrated at the
level of the whole organism, the tissues responsible for this effect as well as the
underlying mechanisms are unknown (Lowell and Spiegelman, 2000). Possibilities
for such tissues include skeletal muscle, liver, white adipose tissue and the heart, and
are sites of interest as they could be relevant to body weight control in humans
(Lowell and Bachman, 2003). Several studies have suggested that the liver may
mediate leptin’s effects on metabolism. This possibility has been suggested based on
the liver’s integral role in lipid metabolism, its significant energetic demands of
~20% of standard metabolic rate (SMR) in the rat (Porter and Brand, 1993), and its
contribution to the catabolic effects of leptin (Cohen et al., 2002). Skeletal muscle and
the heart are other highly metabolic organs (Rolfe and Brand, 1996; Rolfe et al.,
1999), which have also been suggested to play a role in the increased energy
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expenditure associated with leptin treatment. However leptin’s effects on metabolism
or mitochondrial function in these tissues has not been directly studied.
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Chapter 2: Materials and Methods
Leptin Administration
Male C57BL6/J and C57BL6/J ob/ob mice (8-10 weeks old) were purchased
from The Jackson Laboratory (Barr Harbor, ME), and housed in individual cages in a
22oC temperature controlled room, or 30oC incubator (for thermoneutral studies).
Alzet miniosmotic pumps with a flow rate of 0.5 µl/hr were filled aseptically with
either sterile PBS or Leptin (400 ng/µl for ob/ob mice ; 1 µg/µl for wt mice ; 5µg/µl
for wt NC and wt FF mice). The pumps were incubated in a sterile 0.9% NaCl
solution for at least six hours, and implanted s.c. using isoflurane as an anesthetic. For
the withdrawal studies, all pumps were surgically removed from treated and control
animals after eight days, and mice were sacrificed on the fifteenth day (Montez et al.,
2005). For all other studies, mice were sacrificed after twelve days of either saline or
leptin infusion (Cohen et al., 2002). Pair fed animals were implanted with a PBS
pump, and fed the same amount of food that their leptin treated counterparts ate on
the same day.
Isolation of Mitochondria from Liver
Mice were sacrificed by cervical dislocation and mitochondrial isolation was
carried out according to standard procedures (Chappell and Hansford, 1972). Of note,
it was important not to use CO2 to sacrifice the mice, as doing so may uncouple the
mitochondria and greatly affect any assays, including differential centrifugation.
Immediately after sacrifice, livers were excised and rinsed with ice-cold STE buffer
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(250mM Sucrose, 5mM Tris, 2mM EGTA, pH to 7.4). In a beaker, the livers were
chopped with scissors and washed with STE until all the blood was removed. They
were then homogenized in a glass Dounce homogenizer using 7 strokes of a loose
pestle, followed by 3 strokes of a tight pestle, in approximately 40ml of STE. The
homogenate was poured into a falcon tube and centrifuged at 1,047 x g for 3 min at
4° C. The supernatant was transferred to a new falcon tube and centrifuged at 11,630
x g for 10 min at 4° C. The supernatant was discarded and the pellets were gently resuspended with a re-suspending stick. Care was taken not to disturb any blood spot.
STE was added to the re-suspended pellets, and the suspension was transferred to a
clean falcon tube and spun for 10 mins at 11,630 x g. The previous three steps of
discarding the supernatant, re-suspension and centrifugation, were carried out once
more. Finally, the mitochondrial extract was re-suspend in approx 200ul of STE.
Purification of Liver Mitochondria
In the case of liver mitochondria being used for iTRAQ protein analysis,
further purification was done using a 5% to 35% continuous gradient of nycodenz
(Sigma D2158) made in Solution B (0.22M Mannitol, 70mM Sucrose, 1mM EDTA,
10mM MES, pH 7.5). Mitochondria isolated by the method described above were resuspended in Solution B instead of STE in the last step, and loaded onto a continuous
nycodenz gradient [made by mixing 5% and 35% nycodenz in Solution B using a
gradient maker]. The tubes were then centrifuged at 75,000 x g in a Beckman SW41
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Ti swinging-bucket rotor for 2 hours at 4° C). The mitochondrial band was removed
and assayed for protein content using a 2-D Quant Kit (Amersham Biosciences, NJ).
Western Blotting to Assess Mitochondrial Purity
A 12% SDS gel was prepared as follows (recipe for 2 gels): (a) Separation gel
– 2.5ml 40% Acrylamide (29:1), 2.5 ml 4x Buffer, 4ml H20/Glycerol (10:8), 37.5ul
10% APS (fresh or frozen), 7.5ul Temed (b) Stacking gel – 0.65ml 40% Acrylamide
(29:1), 1.25ml 4x Buffer, 3.05ml H20, 25ul 10% APS (fresh or frozen), 5ul Temed.
The separation gel was poured into the chamber first, adding the stacking gel and
comb afterwards, and was allowed to sit for 15 mins to polymerize. Next, the
chamber was filled with running buffer. The gel was run at 70V until the samples
made it through the stacking gel and were in one straight line, after which the voltage
was increased to 140V. The gel was run at this voltage for approximately 1.5 hours
(depending on the percentage of gel).
The sandwich for blotting was prepared by putting the following on the white
side (positive side) of the sandwich maker: a) pad soaked in running buffer, b)
whatman paper, c) membrane, d) gel, e) whatman paper, f) pad soaked in running
buffer. The chamber was filled with blotting buffer and run in the cold room for three
hours at 38V. An ice holder and a stir bar were placed in the chamber to keep the
temperature down. After it had been run, the membrane was blocked for 30-60 mins
with 0.75g of fat-free powdered milk in 15ml of TBS-T. It was then washed with
TBS-T three times for 5 minutes each cycle.
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The 1° antibody was made by adding 0.75g of fat-free powdered milk to 15ml
of TBS-T and the appropriate amount of 1° antibody. The membrane was incubated
with this mixture overnight at 4°C. The next morning, the membrane was washed
with TBS-T three times for at least 8 minutes each cycle. The 2° antibody was then
made by adding 0.75g fat-free powdered milk to 15ml of TBS-T and the appropriate
amount of antibody. The membrane was incubated with this mixture for 30min at
room temperature. After the incubation, the membrane was washed with TBS-T four
times for 15 mins each cycle. Finally, the membrane was dried shortly by waving it in
the air.
Equal volumes of detection reagent 1 and detection reagent 2 (for a total
volume of 750ul for each membrane) were added to the membrane, and it was
covered with saran wrap. In wrapping the membrane care was taken to make sure
there were no air bubbles. The membrane was incubated in this mixture for one
minute, removed, and dried shortly by waving in the air. Next, the membrane was
covered in saran wrap and taped to the top left corner of an exposure cassette. The
film put in the cassette was exposed to the film for 30sec, 1min, 2min, and 5min on
each of the four corners. Finally, the film was put in the developer.
Isolation of Mitochondria from Skeletal Muscle
Mice were sacrificed by cervical dislocation and as much tissue as possible
was harvested from the hamstrings, calf, quadriceps, triceps, and pectoral muscles. As
it was being collected, the skeletal muscle tissue was placed in CPI medium (0.1M
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KCl, 0.05M Tris-HCl, 2mM EGTA, pH 7.4) on ice. At the end of the collection, the
medium was poured away, the tissue was weighed (should have approx 11-12g tissue
/ 5 mice), and more CP1 medium was immediately added to the tissue. A small
amount of tissue was taken and cut with sharp scissors to the smallest pieces possible.
This was repeated until all the tissue has been minced in this way.
The tissue was then chopped further with scissors in a beaker. The muscle was
allowed to sink to the bottom, and the supernatant containing fat, connective tissue
and hair at the top was discarded while being careful not to throw away tissue. The
beaker was then refilled with CP1, and the previous step of chopping / discarding was
repeated two more times (i.e. three total times of chopping and pouring off). On the
last step, instead of adding CP1, 10 milliliters of CP2 (0.1M KCl, 0.05M Tris-HCl,
2mM EGTA, 0.5% BSA(fatted), 5mM MgCl2, 1mM ATP, Protease Type VIII
(Sigma P 5380) @ 245.7units/100ml, pH 7.4 @ 4˚C) was added to beaker the for
every gram of tissue. It is important not to have the CP2 more dilute as this causes
over digestion of the tissue resulting in a poor yield of mitochondria. Keep in mind
that CP2 can be made the day before, but the ATP and protease should be added on
the day of the experiment and the pH rechecked. Also, the solutions should be
dissolved completely before adding MgCl2.
The 250mL beaker with tissue suspended in CP2 was left stirring gently on
ice for 3 min (the timing is very important). The muscle was then allowed to sink to
the bottom, as much CP2 as possible was poured off, and the beaker was filled with
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CP1. The tissue was then transferred into approx 20 round-bottom tubes per
preparation on ice. The Polytron was used on each of the tubes for 20 sec, and the
supernatant was poured into a 50mL falcon tube. Next, the contents of the falcon tube
were transferred to a Dounce homogenizer, and care was taken not to transfer large
chunks. Carefully, the tissue was plunged 5 times with the loose plunger, and 3 times
with the tight plunger. After each plunge, the chunks of tissue were cleaned off the
pestle with a Kimwipe. For large volumes of tissue, the homogenization was done in
two shifts.
After the tissue had been homogenized, it was spun at 4˚C for 10 min at a
speed of 490 x g. The supernatant was transferred to a new tub and filtered through a
70ul cell strainer to remove debris. It was then spun at 4˚C for 10min at 10,368 x g.
Carefully, the supernatant was discarded and the pellet was re-suspended using a “resuspension stick”. The falcon tube containing the sample was then filled with 30ml of
CP1 and care was taken to make sure the entire sample had been re-suspended. The
solution was then transferred to a new falcon tube and the last spin step was repeated.
The supernatant was discarded, the pellet re-suspened, and 180µL of CP1 was added.
At the end, it is important to make sure there are no clumps of protein before
determining the protein concentration using the Biuret method (Gornall et al., 1949).
Isolation of Mitochondria from Heart Muscle
Mice were sacrificed by cervical dislocation, the hearts were removed and
immediately placed in ice cold STE (recipe in previous section). In a beaker, the
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hearts were chopped with scissors and washed with STE until all the blood was
removed. As much STE as possible was poured off, being careful not to lose any of
the minced heart tissue, and was replace with 10mL of STE + 20mg Protease Type
VIII (Sigma P 5380). The suspension was left stirring on ice for 2 minutes. The tissue
was allowed to sink to the bottom, the supernatant was carefully poured off, and the
beaker was filled to 70ML with STE. Next, the contents of the beaker were
transferred to a Dounce homogenizer, plunged 5 times with the loose plunger, and 3
times with the tight plunger.
The resulting suspension was centrifuged for 10 minutes at 4˚C at a speed of
8,000 x g. The supernatant was disposed of and the pellet was re-suspend using a “resuspending stick”. All the protease should have remained in the supernatant, thus
avoiding over-exposure of the mitochondria to the protease. The suspension was
centrifuged for 10 minutes at 4˚C at a speed of 700 x g, the supernatant was decanted
into a falcon tube, and the pellet was disposed of. Next, the falcon tube containing the
supernatant was spun for 10 minutes at 4˚C at a speed of 8,000 x g. Finally, the
supernatant was disposed of, the pellet re-suspended in ice cold STE, and the protein
concentration determined using Biuret.
Isolation of Primary Hepatocytes and Measurement of Basal Metabolic Rate
Murine primary hepatocytes were isolated according to a slightly modified
version of the method developed by Seglen (Seglen, 1976). The portal vein was
cannulated, a suture tied around the cannula, and liver perfusion medium (Invitrogen,
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17701-038) with 0.01M HEPES buffer added and warmed to 37oC was perfused
through the liver for 5 minutes. Next, collagenase medium (HBBS w/out phenol red
from Cellgro, 16mM NaHCO3, 1% FA free BSA, 0.1M HEPES, 0.05% Collagenase
Type IV – Sigma C5138, pH 7.6 at 37oC) warmed to 37oC was perfused for 5
minutes. Liver cells were dispersed and gradient centrifuged in isolation media
(Cellgro DPBS, 1mM sodium pyruvate, 2% FA free BSA, 25mM Dextrose, 0.03M
HEPES, pH 7.6 at 4oC) according to the aforementioned Seglen method. The isolated
hepatocytes were switched to incubation medium (106mM NaCl, 5mM KCl, 25mM
NaHCO3, 0.41mM MgSO4, 10mM Na2HPO4, 2.5mM CaCl2, 10mM glucose, 10mM
lactate, 1mM pyruvate, 2.25% (w/v) FA free BSA, pH 7.4 at 37oC), and respiration
was recorded as outlined previously (Harper and Brand, 1993). To determine leak and
non-mitochondrial respiration, cells were incubated with oligomycin (1.0 ug/ml), and
myxothiazol (1.0um).
Measurement of Mitochondrial Respiration
A Clarke-type oxygen electrode (Dual Digital Model 20, Rank Brothers, UK)
fitted with a circulating water bath (Model 3016H, Fisher Scientific) was used to
measure mitochondrial respiration rate. Mitochondria were suspended in either KHEP
(120uM KCl, 5mM KH2PO4, 3mM HEPES, 1mM EGTA, 0.3% defatted BSA, pH
7.4) or MRS (70mM Sucrose, 43mM KCl, 3.6mM MgCl2, 7.2mM KH2PO4, 36mM
Tris-HCl, 0.3% defatted BSA, pH 7.4) at a concentration of 0.5mg/ml and maintained
at 37oC throughout the recordings. The oxygen solubility of the medium was
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considered to be 406 nmol/ml (Reynafarje et al., 1985). Rotenone (5µM), Succinate
(4mM), ADP (1M), Oligomycin (1µg/ml), and FCCP (0.3µM) were added to the
recording chamber in a stepwise fashion to measure State II, State III, State IV, and
maximal capacity rates. Data were handled and analyzed using a PowerLab 4/20 data
recorder and Chart Pro Software (both from AD Instruments, CO).
Modular Kinetic Analysis
The kinetics of proton leak, substrate oxidation, and ATP turnover were
determined as described previously (Brand, 1995; Brand et al., 1993; Hafner et al.,
1990; St-Pierre et al., 2003). Mitochondrial membrane potential was measured using
a methyltriphenylphosphonium (TPMP+) electrode as described earlier (Brown and
Brand, 1985), using a TPMP+ binding correction of 0.54. Mitochondria were
incubated at a concentration of 0.5mg/ml in KHEP assay medium (composition in
previous section), and maintained at 37oC throughout the assay. For proton leak and
substrate oxidation kinetics, rotenone (5µM), oligomycin (1µg/ml), and nigericin
(0.11 µM) were present at the beginning of each run. For ATP turnover kinetics,
rotenone (5µM), nigericin (0.11 µM), and ADP (0.57mM) were present at the
beginning of each run. TPMP+ was then added up to 1.3µM for calibration, and
succinate (4mM) was fed to the mitochondria as a substrate. Either malonate (proton
leak, and ATP turnover) or FCCP (substrate oxidation) was then gradually added to a
concentration of 1.3mM or 0.85µM, respectively, to reduce the membrane potential.
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At the end of each recording, 1.1µM FCCP was added to determine the drift of the
electrode, if any.
Protein isobaric labeling with iTRAQ reagents
Mitochondria were solubilized with 7 M urea, 2 M thiourea and 100 mM Noctyl-β-D-glucopyranoside and protein concentration determined. Protein (60-100 ug)
was precipitated with acetone (90% final, v/v) at -20oC overnight. For the four-plex
isobaric labeling, separate mitochondrial preparations containing equal amounts of
protein were treated in parallel essentially as described by (Ross et al., 2004). Stock
reagents and buffer (TEAB, SDS, TCEP, MMTS and four isobaric tagging reagents)
are obtained in kit form (Applied Biosystems). Protein (60-100 µg protein) was
suspended in 20 ul 0.5 M TEAB, reduced with 2.5 mM TCEP (40oC for 1 h) and
cysteine residues blocked with 10 mM MMTS (room temperature for 15 min).
Proteolytic digestion was with trypsin (porcine modified, Promega; 1:20, w/w) for 20
h at 40oC. Isobaric tagging iTRAQ reagent (1 unit1 in ethanol) was added directly to
the protein digest (70% ethanol, v/v, final) and the mixture incubated at room
temperature for 1h. The reaction was quenched by addition of 9 volumes 0.1% TFA
in water (Optima grade, Fischer Sci.). The reaction mixtures are combined and stored
at -20oC. Mitochondrial protein from wt (sham), wt (leptin treated), ob (sham) and ob
(leptin treated) animals were isobarically labeled with 114.1, 115.1, 116.1 and 117.1
iTRAQ reagent, respectively, in all experiments.
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SCX Peptide Fractionation
The iTRAQ four-plex-labeled peptide mixture (400, 252 and 276 µg digest for
experiments A, B and C, respectively) was applied to a pair of sulfoethyl aspartamide
SCX spin columns (SEM HIL-SCX, PolyLC, The Nest Group, Inc. Southboro, MA)
equilibrated with 10 mM KH2 phosphate, pH 4.5, 20 % CH3CN. For peptide
adsorption to the column and subsequent washing and elution steps, a centrifugal
force of 400 x g was used. Excess reagent was washed from the column with 800 µl
equilibration buffer. Peptides were eluted with eight 50 µl volumes of KCl in a
stepwise gradient from 50-500 mM KCl in equilibration buffer (i.e. 50, 80, 115, 155,
180, 205, 350 and 500 mM KCl) and fractions were dried in a vacuum centrifuge.
Reverse Phase LC
Peptides in SCX fractions were separated by C18 nano LC using an 1100
Series nano HPLC equipped with µWPS autosampler, 2/10 microvalve, MWD uv
detector (214 nm) and Micro-FC fraction collector/spotter (Agilent). Each SCX salt
step was reconstituted with 43 ml 0.1 % TFA, v/v in water and 40 µl injected. Digest
was trapped on a C18 cartridge (Zorbax300SB, 5 µm, 5 x 0.3 mm; Agilent), desalted
with solvent C (CH3CN:H2O:TFA, 5:95:0.1) at 20 µl/min for 9 min. and effluent
directed to waste. At 9 min post injection,the trapping cartridge was placed ahead of a
C18 column (Zorbax300SB, 3.5 µm, 150 x 0.1 mm; Agilent) equilibrated with solvent
A (H2O:TFA, 99.9:0.1). Peptides were eluted with a gradient of solvent B
(CH3CN:H2O:TFA, 90:10:0.1) from 6.5% B to 50% B over 90 min at a flow rate of
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0.4 µl/min. Column effluent was mixed (micro Tee, Agilent) with matrix (2 mg/ml αCHCA

in

CH3OH:isopropanol:CH3CN:H2O:acetic

acid

(12:33.3:52:36:0.7)

containing 10 mM ammonium phosphate) delivered with a PHD200 infusion pump
(Harvard Apparatus) at 0.9 µl/min. Fractions were spotted at 24 sec. intervals onto
stainless steel maldi targets (192 wells/plate, Applied Biosystems).
Mass Spectrometry
Mass spectra were acquired on an Applied Biosystems 4800 Maldi TOF/TOF
Analyzer (TOF/TOF). MS spectra from 800-3500 Da were acquired for each fraction
from 750 laser shots of a 200 Hz YAG laser operated in the 3rd harmonic (355 nm).
The TOF/TOF was operated in positive ion reflectron mode. Seven point Gaussian
smoothing was applied to spectra and S/N of 30 filter applied for peak picking.
Calibration was done using default mode. Plate calibrants were glu-fibrinopeptide A
(m/z 1714.787), ACTH (m/z 2753.419), angiotensin (m/z 1440.790), bradykinin (m/z
1048.578), and ACTH 1-17 (m/z 2107.197). The twelve most intense peaks in each
MS spectrum were selected for MS/MS analysis. MSMS spectra were acquired from
1500-4000 laser shots using “quality dependent” mode (6 fragment ions at S/N 60);
fragment peak picking used S/N 40. MSMS calibration was done with fragments of
glu-fibrionpeptide A (m/z 430.242, 684.346, 1056.475 and 1441.634). In a reinterrogation of the target plates, additional MS/MS spectra were acquired.
Fragmentation of the labeled peptides was induced by the use of atmosphere as a
collision gas with a pressure of ~ 6 x10-7 torr and a collision energy of 2kV.
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Peptide identifications were performed using GPS Explorer (v3.6, Applied
Biosystems) which acts as a front end for the Mascot search engine (v2.1
MatrixScience, London UK).

Each MS/MS spectrum was searched against IPI

mouse.

with

Trypsin

specificity

one missed

cleavage was selected.

S-

mercaptomethylcysteine and the N-terminal and lysine iTRAQ labels were selected as
fixed modifications. Oxidized methionine was considered as a variable modification.
The precursor tolerance and MS/MS fragment tolerances were set to +/- 0.7 and +/0.3 Da, respectively. A confidence interval (C.I.%) was calculated by GPS Explorer
using Mascot ion score and significance, such that a C.I.% value of 95% is equivalent
to a Mascot ion score at the significance value. The individual peptide identifications
were grouped into protein identifications and assigned a total ion C.I.% by GPS
Explorer.
Liver Triglyceride Levels
Total lipids were extracted from liver as described in previously established
protocols (Bligh and Dyer, 1959). Quantification of fatty acids was done through
liquid chromatography in accordance to previously published methods (Asilmaz et
al., 2004; Miyazaki et al., 2001). For the quantification of fatty acids, pentadecanoic
acid (Sigma-Aldrich) was added as an internal standard.
Mitochondrial Volume Density and Area Measurements
The unbiased stereological method for the assessment of mitochondrial
density was used based upon our published paper (Coppola et al., 2007). The central
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feature of this approach is the use of a systematic random sampling method, which
meets the statistical requirements necessary to insure an unbiased estimate of the
feature of interest. The estimation was performed using the Cavalieri method
(Gundersen et al., 1988; Gundersen and Jensen, 1987) and the optical dissector
method. The assessment of mitochondrial number was determined using the optical
dissector method on electron micrographs. One-way analysis of variance was
performed followed by the Student-Newman-Keuls-test to determine significance of
differences between groups. The statistical confidence was set at P < 0.05.
Lipid Quantification from Purified Hepatic Mitochondria
Samples were isolated by sequential ultracentrifugation. The mitochondrial
fraction from each sample was re-suspended in 200 µL of 50% chloroform and
methanol (v/v). Twenty µL of sample was analyzed by normal phase HPLC-MS.
Lipids were separated on a SUpelcosil –LC-Si column (1 mm * 30 cm; SUPELCO)
on the HP1100 HPLC/ABI QSTAR XL LC/MS system, with ion extraction,
separation, and detection in both positive and negative ion modes. The solvents were
5 mM ammonium acetate in chloroform/MeOH/(IPA)/water (80:10:7:3) (A) and 5
mM ammonium acetate in MeOH/IPA/water(90:7:3) (B). Data were acquired using
information-dependent, automated acquisition. The acquired ms/ms spectra were
analyzed to determine the lipid classes and relative quantities.
General Steps and Lipid Extraction for Measurement of Oxidated Fatty Acids
The Hazen Lab at the Cleveland Clinic carried out this procedure in
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collaboration with our lab. The methods described in this and the next section
discussing measurement of oxidated fatty acids are incorporated from their previously
published methods (Zhang et al., 2002). Free fatty acids were purchased from
Cayman Chemical Company (Ann Arbor, MI). Organic solvents were obtained from
Fisher Scientific Co. (Pittsburgh, PA). All other reagents were purchased from Sigma
unless otherwise indicated. All buffers were passed over a Chelex-100 resin column
(Bio-Rad) and supplemented with 0.1 mM diethylenetriamine pentaacetic acid
(DTPA) to remove potential contaminant transition metal ions that might catalyze
lipid oxidation. Protein content was determined using Bradford-based Bio-Rad
protein assay using IgG as protein standard.
Lipid extraction was carried out next. All steps were performed under either
argon or nitrogen atmosphere. Immediately prior to extraction, 10 ng each of two
deuterated

internal

standards,

12(S)-hydroxy-5,8,10,14-eicosatetraenoic-

5,6,8,9,11,12,14,15-d8 acid (12-HETE-d8) and prostaglandin F2

(PGF2 -d4)

(Cayman Chemical Company) were added to each sample. Hydroperoxides in
samples were then reduced to their corresponding stable alcohols by adding 1 mM
SnCl2 (23). Lipids were then extracted by adding a solvent mixture (1 M acetic
acid/2-isopropanol/hexane (2:20:30, v/v/v) to the sample at a ratio of 2.5 ml of
solvent mixture/1 ml of sample, vortexing, and then adding 2.5 ml hexane. Following
vortex and centrifugation, lipids were recovered in the hexane layer. Peritoneal
lavages were re-extracted by addition of an equal volume of hexane, followed by

53

vortex and centrifugation. The combined hexane layers were dried under N2 flow and
then analyzed following saponification to release all esterified fatty acid oxidation
products. For saponification, N2-dried lipids were resuspended in 1.5 ml of 2isopropanol, and then fatty acids were released by base hydrolysis with 1.5 ml of 0.2
M NaOH at 60 °C for 30 min under argon atmosphere. Hydrolyzed samples were first
acidified to pH 3.0 with 0.5 M HCl, and then fatty acids were extracted twice with 4
ml of hexane. The combined hexane layers were dried under N2 flow, resuspended in
100 l of methanol, and stored under argon at 80 °C until analysis by reverse phase
high performance liquid chromatography (HPLC) with on-line electrospray ionization
tandem mass spectrometry (LC/ESI/MS/MS), as described in the next section.
Lipid Analysis for Measurement of Oxidated Fatty Acids
LC/ESI/MS/MS was employed to quantify the multiple distinct oxidation
products of arachidonic acid and linoleic acid, including individual HETEs, F2isoprostanes, and hydroxy-octadecadienoic acids (HODEs). Immediately prior to
analysis, one volume of H2O was added to 20 volumes methanol-suspended sample,
which was then passed through a 0.22- m filter (Millipore Corporation, Bedford,
MA). Sample (50 l) was injected onto a C-18 column (2

250 mm, 5 m ODS)

(Phenomenex, Rancho Palos Verdes, CA) at a flow rate of 0.2 ml/min. The separation
was performed using a gradient starting from 85% methanol over 15 min, then to
100% methanol over 1 min, followed by 100% methanol for 15 min. HPLC column
effluent was split so that only 50% was introduced into a Quattro II triple quadrupole
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mass spectrometer (Micromass, Inc.).
Analyses were performed using electrospray ionization in negativeion mode
with multiple reaction monitoring of parent and characteristic daughter ions specific
for each isomer monitored. The transitions monitored were mass-to-charge ratio
(m/z): m/z 295 3 171 for 9-HODE; m/z 2953195 for 13-HODE; m/z 2793261 for
linoleic acid; m/z 3193115 for 5-HETE;m/z 3193155 for 8-HETE;m/z 3193151 for 9HETE;m/z 319 3 167 for 11-HETE; m/z 319 3 179 for 12-HETE; m/z 319 3 175 for
15-HETE; m/z 303 3 259 for arachidonic acid; m/z 327 3 184 for 12-HETE-d8; m/z
353 3 309 for F2-isoprostanes; and m/z 357 3 313 for PGF2 -d4. The nitrogen curtain
gas-flow rate was 5 liters/min and nebulizer gas-flow rate was held at 0.2 liters/min.
Collision-induced dissociation was obtained using argon gas. The internal standard
12-HETE-d8 was used to for quantification of HETEs as well as to calculate
extraction efficiencies of HODEs and HETEs (which were

85%). The internal

standard PGF2 -d4 was used to for quantification of F2-isoprostanes.
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Chapter 3: Results
Quantitation of Leptin’s Effects on Thermogenesis and Metabolism
Resting core body temperature in leptin deficient ob/ob mice is significantly
lower than in their wild-type control littermates, and leptin treatment of these mutant
mice restores their core body temperature to normal/wild-type levels (Figure 9A).
This indicates that a proportion of leptin’s metabolic effects in ob mice are a result of
increased thermogenesis and subsequent restoration of core body temperature. In
order to assess whether there are metabolic effects in addition to this, we treated a
second group of ob mice with leptin under thermoneutral conditions. Ob/ob mice
housed at 30oC, the temperature at which metabolic energy is not required to maintain
core temperature (Gordon, 1993), have core body temperatures that are not
significantly different from their littermates controls. Leptin treatment of ob/ob mice
housed at this temperature does not significantly alter core body temperature (Figure
9A).
In order to test whether leptin has additional metabolic effects under these
conditions, we compared the effects of leptin treatment to pair feeding of ob/ob mice
at both 22oC and 30oC. The group treated with leptin at 22oC followed the established
trajectory of weight loss (Halaas et al., 1995), and lost fat mass equivalent to 36.5%
of their body weight in two weeks (Figure 9B). In comparison, mice pair fed at
thermoneutral temperatures lost 13.8% of their body weight during the same time
period, indicating that approximately two fifths of leptin-mediated weight loss is due
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Figure 9. Components of leptin mediated weight loss. (A) ob/ob mice
have a lower core body temperature than wt mice, which is corrected by
leptin infusion. Housing the mice at thermoneutral temperatures increases
the core body temperature of ob/ob mice and diminishes the significance of
body temperature correction by leptin. (B) By leptin treating and pair feeding
mice at room and thermoneutral temperatures, we were able to distingush
the different components of leptin mediated weight loss. Arrow 1 represents
weight loss due to leptin's correction of body temperature. Arrow 2
represents weight loss due to leptin's induction of satiety. Arrow 3 represents
wight loss due to leptin mediated increases in energy expenditure and basal
metabolic rate.
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to the induction of satiety (Figure 9B, arrow 1). Leptin treated animals housed at 22oC
lost 12% more weight than animals receiving the hormone at 30oC. Similarly, pair fed
animals housed at 22oC also lost 12% more weight than animals receiving the same
treatment at 30oC. These findings suggest that approximately one third of leptinmediated weight loss is due to the normalization of body temperature (arrow 2).
Another observation we made was that leptin treated animals lost 11% more weight
than pair fed animals when housed at 22oC. Leptin treated animals housed at 30oC
also lost 11% more weight than their pair fed counterparts. These findings indicate
that the remaining one third of leptin-mediated weight loss is due to increases in
energy expenditure and basal metabolic rate (arrow 3) (p<0.0001 for all
comparisons).
Having shown that leptin has metabolic effects beyond normalizing core
temperature, we next set out to analyze which tissues contribute to the increased
energy expenditure discussed above. We started our investigation with the liver
because of several reasons. First of all, the organ plays an integral role in lipid
metabolism (Bell, 1979). Secondly, the liver is responsible for approximately 20% of
the standard metabolic rate (SMR), and thus has significant energy demands (Porter
and Brand, 1993). Finally, the liver is known to be an integral player in some of the
catabolic effects of leptin (Cohen et al., 2002). Therefore, the liver made a good
candidate organ for the location of the changes in metabolism we were interested in
investigating further.

58

Livers from ob mice are markedly steatotic and 12 days of leptin treatment at
ambient temperature corrects this abnormality (Figures 10A and 10B). In order to
determine the mechanisms by which leptin carries out this correction, we measured
the liver triglyceride (TG) levels of leptin treated and pair fed ob mice housed at both
22oC and 30oC. Animals receiving leptin treatment at 22oC had liver triglyceride
levels of 439µM/g, as opposed to 670µM/g for those treated with the hormone at
30oC (Figure 10C). Likewise, animals pair fed at 22oC had liver triglyceride levels of
664µM/g, as opposed to 906µM/g for those receiving the same treatment at 30oC.
These data suggest that the steatosis was in part corrected by leptin-mediated
normalization of body temperature (p<0.01) (Figure 10C, arrow1). Furthermore,
leptin treatment at 22oC reduced liver triglyceride levels by approximately 225µM/g
over pair feeding at the same temperature (439µM/g vs. 664µM/g) (Figure 10C).
Similarly, leptin treatment at 30oC reduced liver triglyceride levels by approximately
236µM/g over pair feeding (670µM/g vs. 906µM/g). These findings indicate that the
steatosis is also corrected in part by leptin-mediated increases in energy expenditure
and basal metabolic rate (p<0.01).
Leptin Levels Influence Hepatocyte Metabolism
Since our data showed a role for leptin-mediated increases in energy
expenditure in the liver, we wanted to see if we could measure such changes.
Therefore, we analyzed the effects of leptin pre-treatment on freshly isolated primary
hepatocyte metabolism. Each day recordings were made from one ob/ob + lep animal
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Figure 10. Leptin-Mediated Correction of Hepatic Steatosis. (A) Ob/ob mice have livers
exhibiting severe steatosis, which is amended by leptin restoration for 12 days (B). (C)
Leptin-mediated correction of hepatic steatosis has one component which is correlated with
leptin's correction of body temperature (Arrow 1), and another with leptin-mediated increases
in energy expenditure (Arrow 2).
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and one ob/ob + pbs animal. To correct for daily variances in recordings due to
differences in the freshly made solutions, membrane permeability, and variable
precipitation on the electrodes, we normalized the data by dividing the values from
both groups by the total respiration recorded for that day. This gave us a “normalized
ratio” that we could use to compare the rates between the leptin treated and pbs
treated groups on different days.
Twelve-day leptin treatment of ob/ob mice reduces the primary hepatocyte
basal metabolic rate normalized ratio from 0.63 to 0.37 (Figure 11A) (p<0.0001). The
addition of oligomycin to the solution inhibits Complex V of the mitochondrial
electron transport chain, and stops coupled respiration – i.e. respiration that results in
the formation of ATP. In this scenario, since coupled respiration has been halted, any
respiration that is recorded is due to uncoupled respiration, more commonly referred
to as mitochondrial leak. Upon addition of oligomycin in our recordings, the leak
component of primary hepatocyte basal metabolic rate is reduced from 64.8% to
41.7% with leptin treatment (Figure 11B)(p<0.05). These findings indicate that there
is a leptin-mediated reduction in the amount of uncoupled respiration. At the end of
each recording, we add myxothiazol to determine the non-mitochondrial respiration
in the hepatocytes so it can be corrected for in the respiration rates (See methods).
However, when we look at the non-mitochondrial respiration itself, we see
differences between the two treatment groups. Twelve-day leptin treatment of ob/ob
mice reduced the non-mitochondrial oxygen consumption normalized ratio in primary
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Figure 11. Primary Hepatocytes from ob/ob mice plus/minus
leptin. (A) Twelve day leptin treatment of ob/ob mice reduces primary
hepatocyte basal metabolic rate. (B) The leak component of basal
metabolic rate, i.e. uncoupled respiration, is also decreased with leptin
treatment. (C) Finally, leptin treatment decreases non-mitochondrial
respiration as well. = p < 0.05
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hepatocytes from 0.79 to 0.21 (p<0.01). Therefore, leptin is having affects on both
mitochondrial and non-mitochondrial respiration, which is further explored in the
discussion section that follows.
Leptin Inhibits Hepatic Mitochondrial State Two, Four, and FCCP Rates
To test what effects the observed leptin-mediated changes in primary
hepatocyte metabolism may be having on mitochondria in these cells, we measured
the different components of mitochondrial respiration. Since we had demonstrated
that mitochondrial leak was affected in the hepatocytes treated with leptin, we first
wanted to look at the respiratory control ratio (RCR) of hepatic mitochondria. This
measure is the ratio of coupled respiration over uncoupled respiration (i.e. leak). RCR
is lower in ob/ob mice (2.43) than in wt mice (4.64) (p<0.05) (Figure 12). This
difference disappears with leptin treatment of the ob/ob animals, as the RCR of leptin
treated ob/ob mice (5.58) is significantly higher than that of saline treated ob/ob mice
(2.43) (p<0.01).
To determine the cause underlying these changes in RCR, we measured state
two, three, four, and respiratory capacity rates. State two and four rates give insight
into the leak component of respiration, while state three and respiratory capacity rates
provide insight into the coupled component of respiration. Our recordings showed
that state two rates were higher in ob mice (55.3 nmolO2/min/mg mito) than in wildtype mice (28.9 nmolO2/min/mg mito)(Figure 13A)(p<0.05). Leptin treatment of the
ob/ob mice reduced the state two rates down to 39.8 nmolO2/min/mg mito, and thus
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+ BSA media in ob/ob and the effect is reversed by leptin infusion. n=5 for
all points, and each was done in duplicate.
= p < 0.01 ; = p < 0.05
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Figure 13. Liver mitochondria leak analysis from Ob/Ob and Wt
mice plus/minus leptin. (A) State 2 and (B) State 4 rates are higher in
ob/ob mice, which initially suggested that a higher proton leak in ob/ob
may be the cause behind the observed changes in the RCR. n=5 for all
points, and each was done in duplicate. , = p < 0.01 ; , = p < 0.05
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diminished the difference between ob/ob and wild-type mice. State four rates are also
higher in ob mice (116.0 nmolO2/min/mg mito) than in wt mice (41.9
nmolO2/min/mg mito). Similar to its effects on state two rates, leptin treatment of
ob/ob mice reduces state four rates to 44.36 nmolO2/min/mg mito, thus bringing them
to wild-type levels. These initial data suggest that a higher proton leak in ob/ob mice
may be the cause behind the observed differences in the RCR. Since an increased leak
in ob/ob animals that is reduced to wild-type levels with leptin treatment is the
opposite of what we would have expected, and since both state two or four rates come
with caveats regarding their interpretation, we conducted modular kinetic analysis to
study these rates in closer detail in the next section.
Having taken a closer look at the denominator of RCR, i.e. uncoupled
respiration, we wanted to take a look at the numerator, coupled respiration. As
mentioned earlier, state three and FCCP rates provide insight into this component of
respiration, and were thus studied next. State three rates are not significantly different
between ob/ob and wt animals, and do not change with leptin treatment (Figure 14A).
Slight differences seem to be present in the means of the rates between the groups,
and perhaps with more repeats these would become significant. On the other hand,
FCCP rates, which represent mitochondrial respiratory capacity, are higher in ob/ob
mice (232.8 nmolO2/min/mg mito) than in wild-type mice (166.0 nmolO2/min/mg
mito)(Figure 14B) (p<0.01). Leptin treatment of the ob/ob mice reduces FCCP rates
to 199.1 nmolO2/min/mg mito, and thus diminishes the difference between ob/ob and
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Figure 14. Liver mitochondria substrate oxidation analysis from
Ob/Ob and Wt mice plus/minus leptin. (A) State 3 and (B) FCCP rates
decrease with leptin treatment, suggesting that the hormone may have
effects on the substrate oxidation system. n=5 for all points, and each
was done in duplicate. , = p < 0.01 ; , = p < 0.05
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wild-type animals. These data suggest that ob/ob mice have a higher substrate
oxidation capacity, which is reduced to wild-type levels with leptin treatment. This
possibility is explored further in the next section, where the results of modular kinetic
analysis into substrate oxidation capacity are presented.
Since no in vitro study can exactly replicate physiological conditions in vivo,
the artificial environment created by different recording solutions can greatly affect
observed mitochondrial respiration rates. Bovine serum albumin (BSA) was present
in the recording solution we were using for the recordings described above. The logic
behind this was that BSA removes free fatty acids that are in the solution, which can
interact with mitochondria to change the inner membrane potential. Though the
removal of these free fatty acids is most likely beneficial to our recordings, we didn’t
know exactly what affect it may be having on the respiration rates. For this reason we
did recordings with a solution that was exactly the same as the one used above, except
it was missing BSA. In these recordings we found that the respiratory control ratio
(RCR) was still significantly lower in ob/ob animals as compared to their wild-type
littermates (Figure 15A)(p<0.05). Furthermore, leptin treatment also normalized
ob/ob rates back to wild type levels in this solution without BSA. Similarly, state two
and four rates were significantly lower in wild-type versus ob/ob mice (p<0.05 and
p<0.01, respectively), and were both brought towards wild-type levels in leptin
treated ob/ob mice (Figure 15B and C). Since these results are similar to those
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Figure 15. Liver mitochondria respiratory analysis from Ob/Ob
and Wt mice plus/minus leptin without BSA in solution. (A) RCR,
(B) State II respiration, and (C) FCCP rates are not affected by the
presence (Figure 14) or absence (Figure 15) of BSA in the recording
solution, suggesting that free fatty acids are most likely not affecting
recording rates. n=5 for all points, and each was done in duplicate. =
p < 0.01 ; = p < 0.05
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observed in the solution containing BSA, we can conclude that BSA is most likely
not affecting our recordings in any significant way.
In our efforts to be thorough with the hepatic mitochondrial recordings, we
had come across two commonly used recording solutions. As discussed above, the
composition of the solution used can have a great impact on the rates one records, and
thus we wanted to see if there were any differences when recording with this second
solution. RCR recordings done in the new solution, called KHEP solution (details in
methods section), did not show a difference between ob/ob mice and wild-type mice
(Figure 16A). Furthermore, we did not observe a change in RCR with leptin treatment
of ob/ob mice when recording from mitochondria in this solution. Similar to the
results seen in the other two solutions, state two respiration was significantly lower in
wild-type mice as compared to ob/ob mice (Figure 16B)(p<0.01), a difference that
was reduced with leptin treatment of the ob/obs. Furthermore, FCCP rates were also
significantly lower in wild-type mice as compared to ob/ob in the KHEP solution
(Figure 16C)(p<0.01). This difference was slightly reduced with leptin treatment, to
the point where it became statistically insignificant. Thus in the KHEP solution, RCR
rates look different than they do in the other solutions, while state two and FCCP
rates look similar to those seen before.
Leptin Inhibits the Hepatic Substrate Oxidation System
To further explore the leptin-mediated changes in mitochondrial leak and
substrate oxidation capacity discussed above, we conducted modular kinetic analysis.
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Figure 16. Liver mitochondria respiratory analysis from Ob/Ob
and Wt mice plus/minus leptin in KHEP solution. Since there are
two mainstream recording solutions used for mitochondrial
respiration recordings, we wanted to check if our findings are seen in
both. (A) The previously observed leptin-mediated changes in RCR
are not seen in KHEP recording solution. (B) State II respiration, and
(C) FCCP rates are still reduced with leptin treatment, suggesting
that the change in solution had little effect on them.. n=5 for all
points, and each was done in duplicate. = p < 0.01 ; = p < 0.05
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In these studies, mitochondrial oxygen consumption is measured with a Clarke
electrode, while the mitochondrial inner membrane potential is measured with a
TPMP electrode simultaneously (see methods). This allows one to plot changes in
respiration as a function of membrane potential, which gives insight into the kinetics
underlying mitochondrial respiration rates. Since one can fully appreciate the inner
workings of mitochondrial respiration through this method, it is considered to be the
“gold standard” of recordings. The difficulties in conducting these recordings attest to
the general preference for the use of state two, three, four and FCCP rates instead,
which in most cases are sufficiently thorough. In our case, however, we wanted to
explore the leak and substrate oxidation findings further, and thus turned to modular
kinetic analysis.
In the first set of recordings, we blocked the phosphorylation system with
oligomycin, and induced an increase in leak with a titration of FCCP. This causes the
proton gradient across the inner mitochondrial membrane to dissipate, and we can see
how these changes affect the substrate oxidation system. When we conducted these
recordings, we found that the substrate oxidation system is increased in ob/ob mice in
comparison to wt mice (Figure 17). Twelve-day leptin treatment of these ob/ob mice
reduces the substrate oxidation capacity of their hepatic mitochondria back towards
wild-type levels. These findings can account for the changes in FCCP rates observed
in the previous section.
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Figure 17. Modular Kinetic Analysis of Leptin's Actions in Hepatic Mitochondria. The substrate
oxidation system is increased in ob/ob and partially reversed by leptin. n=5 for all points, each
done in duplicate.
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In the second set of recordings, we blocked the phosphorylation system with
oligomycin like before, but this time we titrated with malonate to block the substrate
oxidation system. This again caused the proton gradient across the inner
mitochondrial membrane to dissipate, and we could see how these changes affected
mitochondrial proton leak. Our recordings show that hepatic mitochondrial leak is not
different between ob/ob mice and wild-type mice (Figure 18A). Furthermore, leptin
treatment does not change mitochondrial leak as the previously recorded state two
and four respiration rates had indicated. The reason behind the observed differences is
further elaborated upon in the discussion section.
Finally, in the last set of recordings, we just titrate with malonate to block the
substrate oxidation system. Once again, this causes the proton gradient across the
inner mitochondrial membrane to dissipate. Since there is no blockage of proton leak
in this case, our recordings will show the dependence of both leak and the
phosphorylation system on the mitochondrial inner membrane proton gradient. By
subtracting the leak observations from these recordings, we can study the
phosphorylation system in isolation. Our recordings show that the hepatic
mitochondrial phosphorylation system is not different in ob/ob mice as compared to
wild-type mice (Figure 18B). Furthermore, leptin treatment does not affect this
system in either ob/ob or wild-type mice.
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Figure 18. Modular Kinetic Analysis of Leptin's Actions in Hepatic Mitochondria. Neither the
leak (A) nor the phosphorylation system (B) change with leptin treatment of ob/ob mice. n=5
for all points, each done in duplicate.
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Leptin’s Effects on Liver Metabolism Are Independent of its Effects on Hepatic
Fat Stores
Leptin’s effects on the components of liver metabolism of ob/ob mice
discussed above could be the result of its ability to correct steatosis and/or a
consequence of normalizing circulating leptin levels. To distinguish between these
possibilities, we employed a leptin protocol study, in which wild-type mice were
given high doses of leptin (2.5mg/hour) for eight days to completely deplete their fat
reserves. Upon the cessation of leptin treatment, the mice were divided amongst two
groups: free fed (FF) and normo-caloric (NC). The FF animals were allowed to
consume as much food as they wanted to for the next seven days - they quickly
regained their fat mass and restored normal levels of circulating leptin. Each NC
animal was fed the same amount of food it had consumed while on leptin treatment
for the seven days after leptin withdrawal - these mice became hypoleptinemic as
they could not produce the hormone themselves without adipose tissue. A group of
littermates were infused with, and withdrawn from PBS alongside the leptin groups to
serve as a further control. Since wild-type mice do not develop hepatic steatosis, this
study allowed us to analyze the effects of leptin deficiency independently of any
changes resulting from the treatment of hepatic steatosis.
In this study, the RCR was not significantly different in the hepatic
mitochondria of hypoleptinemic NC mice as compared to PBS treated controls
(Figure 19). Furthermore, the re-establishment of leptin levels in the FF mice did not
cause a difference in RCR to arise. These results call for further investigation into
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Figure 19. Liver mitochondrial RCR from wt mice with/without
hypoleptinemia. To determine whether the observed change in substrate
oxidation kinetics (figure 17) is a secondary response to steatosis, attempting to
increase ox phos rates in the face of compromised fatty acid oxidation, we looked
at miotchondria from mice with hypoleptinemia but not steatosis. Our results show
that RCR is not lower in hypoleptinemic "Wt Lep NC" mice, unlike ob/ob mice. This
calls for further investigation into the components of RCR, which is shown in the
next figure. n=5 for all points, and each was done in duplicate.
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coupled and uncoupled respiration rates in order to determine the differences between
leptin’s actions in the presence or absence of hepatic steatosis.
Looking at uncoupled respiration, we found that state two rates were not
significantly different in hypoleptinemic NC mice as compared to PBS treated
controls (Figure 20A). Furthermore, these rates were not changed by the reestablishment of circulating leptin levels in the FF mice. Similarly, state four rates
were also not significantly different in the NC mice (Figure 20B). Again, the FF mice
did not show any differences when compared to both the NC and PBS groups. Thus
under conditions where hypoleptinemia does exist but hepatic steatosis does not, there
is no evidence of a change in proton leak with leptin treatment. These results are
consistent with the data obtained by modular kinetic analysis of ob/ob mice in the
previous section.
We next turned our attention to the numerator of RCR, i.e. coupled
respiration, in these hypoleptinemic mice. State three respiration rates were not
different in NC mice versus PBS mice, and leptin normalization in the FF mice did
not alter these rates either (Figure 21A). However, similar to leptin treatment of ob/ob
mice, the oxygen consumption in the presence of FCCP was significantly higher in
hypoleptinemic mice (186.1 nmolO2/min/mg mito) versus that in PBS treated controls
(152.0 nmolO2/min/mg mito)(Figure 21B)(p<0.01). Furthermore, re-establishment of
circulating leptin levels in FF mice reduced the FCCP rates back down to PBS treated
levels (154.0 nmolO2/min/mg mito)(p<0.01). These data show that in the case of
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Figure 20. Liver mitochondrial leak from wt mice with/without hypoleptinemia.
Neither State 2 (A) nor state 4 (B) rates are different in hypoleptinemic mice, so there
is no sign of changes in proton leak. This is similar to observations in ob/obs. n=5 for
all points, and each was done in duplicate. , = p < 0.01
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Figure 21. Liver mitochondrial substrate oxidation from wt mice
with/without hypoleptinemia. Though State 3 rates do not change (A), FCCP
rates are higher in hypoleptinemic mice, and decrease upon restoration of
leptin levels (B). This is similar to the leptin-mediated decrease in the substrate
oxidation system seen in ob/ob mice. Therefore, we can conclude that leptin's
control over the hepatic mitochondrial substrate oxidation system is most likely
independent of its effects on hepatic fat stores. n=5 for all points, and each was
done in duplicate. , = p < 0.01

80

hypoleptinemia without the presence of hepatic steatosis, mitochondrial respiratory
capacity is still significantly reduced. Furthermore, re-establishment of leptin levels
without any change in hepatic fat stores still significantly decreases the mitochondrial
respiratory capacity down towards wild-type levels. Since the effects of leptin in this
study on both uncoupled and coupled respiration were the same as what was recorded
during modular kinetic analysis of ob/ob mice, these data suggest that leptin’s effects
on hepatic metabolism are not secondary to its ability to reduce hepatic lipid content.
Leptin Levels Influence Mitochondrial Morphology
Mitochondrial morphology is closely linked to the metabolic state of the
organelle, and can give great insight into its function. The observation that leptin
modulates mitochondrial metabolism led us to next assess mitochondrial morphology
and mass before and after leptin treatment using electron microscopy on PBS treated,
leptin treated, and pair fed ob/ob mice. The mitochondria of 12-day PBS treated
ob/ob mice have both normal cristae structure and morphology (Figure 22). A total of
54 micrographs from n=5 mice were studied and yielded similar results. Similarly,
the mitochondria of 12-day pair fed ob/ob mice also had normal cristae structure and
morphology (Figure 23). In this case, 53 micrographs from a total of n=5 mice were
studied and yielded similar results. Interestingly, the mitochondria of 12-day leptin
treated ob/ob mice (Figure 24) were morphologically different from both control
groups and exhibited a less dense, “ballooned” appearance compared to those of 12-
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Figure 22. Electron Microscopic Analysis of Hepatic Mitochondrial
Structure. Mitochondria in the hepatocytes of PBS treated ob/ob mice
have both normal cristae structure and density. A total of 54
micrographs from n=5 mice were studied and yielded similar results.
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Figure 23. Electron Microscopic Analysis of Hepatic Mitochondrial
Structure. Mitochondria in the hepatocytes of pair fed ob/ob mice
have both normal cristae structure and density. A total of 53
micrographs from n=5 mice were studied and yielded similar results.
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Figure 24. Electron Microscopic Analysis of Hepatic Mitochondrial
Structure. Mitochondria in the hepatocytes of leptin treated ob/ob
mice look less dense and “ballooned” compared to those from PBS
treated (figure 22) and pair fed (figure 23) ob/ob mice. The cristae
structure also looks quite different in the leptin treated animals
compared to the other groups. A total of 51 micrographs from n=5
mice in this group were studied and yielded similar results.
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day pair fed and 12-day PBS treated ob/ob mice. The cristae structure was also
different in the leptin infused group compared to the others.
Having found structural differences in mitochondrial morphology and cristae
structure with leptin treatment, we wanted to see if there were any differences in
mitochondrial mass in the hepatocytes. Stereological assessment of these micrographs
showed that hepatocytes from leptin treated ob/ob animals have a decreased
mitochondrial numerical density of 1.57 mito/µm3 (Figure 25A), in comparison to
2.55 and 2.99 mito/µm3 for saline treated and pair fed ob/ob animals respectively
(p<0.01 for both comparisons). Furthermore, leptin treatment also decreases
mitochondrial volume density in ob/ob mice to 0.154 µm3/µm3 (Figure 25B),
compared to 0.245 and 0.281 µm3/µm for saline treated and pair fed ob/ob controls
respectively (p<0.05 for both). Leptin treatment, however, does not alter the average
area of each individual mitochondrion with respect to saline treatment (0.90 vs 0.97
µm2)(Figure 25C). On a side note, it appears that pair feeding increases individual
hepatic mitochondrial size in comparison to both leptin treatment and saline infusion
(p<0.05 for both). These data suggest that leptin treatment leaves each hepatocyte
with fewer mitochondria of the same size, the implications of which are explored in
more detail in the discussion section.
Proteomic Changes Underlying Leptin’s Effects on the Liver
We next set out to investigate whether changes in the levels of specific
mitochondrial proteins were associated with the functional and morphologic changes
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Figure 25. Electron Microscopic Analysis of Hepatic
Mitochondrial Morphology. Both mitochondrial numerical
density (A) and volume density (B) are decreased with leptin
treatment. Theaverage size of each mitochondria, however,
is unaffected by treatment with leptin (C). , = p < 0.01
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86

that were observed. Mitochondria from untreated ob/ob, leptin treated ob/ob, saline
treated wt, and leptin treated wt mice were purified over a nycodenz gradient using a
standard centrifugation protocol (see methods). The protein content of equal numbers
of mitochondria was quantitated using the iTRAQ system. This method of protein
measurement uses four isobaric tags with different reporters, which in tandem mass
spectrometry allow one to accurately quantify differences as small as 10% among
samples (Keshamouni et al., 2006).
Three proteins that are components of the electron transport chain –
cytochrome c oxidase subunit IV, cytochrome c oxidase subunit VIa, and
mitochondrial NADH dehydrogenase – were significantly altered by changes in leptin
levels (Figure 26). Protein levels of cytochrome c oxidase subunit IV showed no
significant difference between ob/ob and wild-type mice, but were decreased to
approximately 83% of their levels with leptin treatment in ob/obs (p<0.01).
Cytochrome c oxidase subunit VIa protein levels, on the other hand, were found to be
increased by 1.23 fold in ob/ob mice versus wild type mice (p<0.05), and leptin
treatment of these ob/obs brought the level of these proteins down to 81% of their
normal values (p<0.05). Finally, protein levels of mitochondrial NADH
dehydrogenase were shown to be 1.53 fold higher in ob/ob mice versus wild-type
mice (p<0.05), and were brought down to 77% of their normal values by leptin
treatment in these ob/obs (p<0.05). The implications of the concerted increase in
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Figure 26. iTRAQ Protein Quantification of Hepatic Mitochondrial Proteins. Three proteins that help comprise the electron transport
chain – cytochrome c oxidase subunit IV, cytochrome c oxidase subunit VIa, and mitochondrial NADH dehydrogenase – are significantly
altered by changes in leptin levels. The increase in the abundance of these proteins during leptin deficiency and their decrease during
leptin infusion may be the mechanism behind the observed differences in hepatic mitochondrial substrate oxidation described earlier.
Also intriguing are the differences seen in the levels of the enzyme ELOVL5, which exhibited the highest increase in abundance during
leptin deficiency, as well as the greatest decrease in abundance with leptin treatment.

these proteins during leptin deficiency and decrease with leptin treatment is explored
in further detail in the discussion section.
Another interesting protein that was found to vary with leptin levels was the
enzyme ELOVL5, which had the highest increase in abundance during leptin
deficiency, as well as the greatest decrease in abundance with leptin treatment (Figure
26). This enzyme is involved in long chain fatty acid elongation, and its induction
has been shown to cause massive hepatic accumulation of mono-unsaturated fatty
acids (Wang et al., 2006). ELOVL5 protein levels were increased by 3.49 fold in
ob/ob mice versus wild-type mice (p<0.05), and leptin treatment of these ob/ob
animals reduced the levels of this enzyme to 53% of its normal abundance (p<0.05).
The implication of these changes in leptin-mediated correction of hepatic steatosis is
explored in the discussion section.
Leptin’s Effects on Hepatic Mitochondrial Lipids
Having found significant changes in mitochondrial proteins induced by leptin,
we next wanted to see if there were any changes in mitochondrial lipids brought about
by the hormone. To do this we purified mitochondria using the same nycodenz
gradient centrifugation protocol that was used for protein quantification in the
previous section (see methods). Lipids were then eluted and separated by normal
phase HPLC from the same number of mitochondria in each sample. The profile of
lipid classes obtained by this method is shown in figure 27A. When tandem mass
spectrometry (ms-ms) profiles were obtained from these lipids, it became clear that
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Figure 27. Leptin-Mediated Changes in Hepatic Mitochondrial Cardiolipin Levels.
(A) Elution profile of lipid classes separated by normal phase-HPLC (B and C)
Cardiolipin levels in hepatic mitochondria are much higher in ob/ob mice than in
wild-type mice, a difference that is corrected by leptin treatment. CL: cardiolipin,
FA: Fatty Acid, PI: Phosphotidylinositol, PE: Phosphotidylethanolamine,
PC: Phosphotidylcholine, SM: Sphigomyelin, LPC: lysophosphotidylcholine
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cardiolipin levels were much higher in ob/ob + PBS mitochondria than in wt + PBS
mitochondria, and this difference was corrected by leptin treatment (Figure 27B).
Indeed, quantification of the lipids showed that cardiolipin levels were more than four
times higher in ob/ob mice than in wild-type mice (relative concentrations of 86
versus 21)(Figure 27C). Leptin treatment brought down the lipid to a relative
concentration of 11units.
Leptin’s Effects on Hepatic Reactive Oxygen Species
It has been shown that modifications of mitochondrial respiration can cause
subsequent changes in reactive oxygen species (ROS) levels, both in vitro and in vivo
(Ambrosio et al., 1993; Chance et al., 1979). Since our study found that leptin
treatment of ob/ob mice alters mitochondrial substrate oxidation, we wanted to see
what, if any, effects this may be having on the formation of ROS. Free radicals in
vivo react with fatty acids and amino acids to form byproducts that can subsequently
be measured to gain a sense of the ROS load in the tissue. To take a deeper look at the
effects of leptin on ROS levels, we measured oxidated fatty acid (oxFA) levels from
the livers of wild-type + saline, wild-type + leptin, ob/ob + saline, ob/ob + 2 days
leptin, and ob/ob + 12 days leptin mice. The results were normalized in two ways and
each of them shows a slightly different result. For the sake of thoroughness, I will
present both findings in this section.
In the first way of normalizing the measurements, the levels of oxFA are
expressed as a ratio between the oxFA and its precursor (for example HETE /
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arachidonic acid, or HODE / linoleic acid) This normalization method probably
results in the truest measurement of oxidative stress, as increased amounts of
precursor will be associated with a proportional increase in the specific oxFA due to
mass action. Since we are looking at the ratio of the oxFA and its precursor,
differences in starting levels of precursor should be canceled out my employing this
method of analysis. When analyzing the results in this method, we find that ob/ob
mice have higher levels of nearly each of the twelve oxFA measured in liver tissue
(Figure 28). Two days of leptin treatment seems to increase these levels slightly,
whereas tweleve days of treatment with the hormone seems to increase oxFA levels
even more. Though none of the differences observed are statistically significant as
they stand, our collaborators believe that they will reach significance with the
analysis of more samples.
The second method of normalization involves dividing the measured levels of
oxFA by the total mg of soluble protein in the liver homogenate. By conducting our
analysis in this way we found that ob/ob mice had very low levels of the twelve oxFA
measured in comparison to wild-type mice (Figure 29). Two days of leptin treatment
partially raised oxFAs back to wild-type levels, and twelve days of treatment with the
hormone pretty much restored wild-type levels for most of the oxFAs. Again, while
none of the differences observed are statistically significant as they stand, our
collaborators believe that they will reach significance with the analysis of more
samples.
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Figure 28. Oxidated Fatty Acids Normalized to their Precursors. Initial trends suggest that ob/ob mice have higher amounts
of oxFA/precursor in liver homogenate than wild-type mice. Leptin treatment of these ob/ob mice seems to increase the levels
of oxidated fatty acids even further. Though none of the difference are statistically significant as they stand, our collaborators
believe that they will reach significance with the analysis of more samples.
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Figure 29. Oxidated Fatty Acids Normalized to the Amount of Protein. Initial trends suggest that ob/ob mice have lower amounts
of oxFA/mg soluable protein in liver homogenate than wild-type mice. Leptin treatment of these ob/ob mice restores the levels
of oxidated fatty acids back to wild-type levels. Though none of the difference are statistically significant as they stand, ou
collaborators believe that they will reach significance with the analysis of more samples.

Leptin Affects Skeletal Muscle Mitochondrial Respiration
Having completed our comprehensive study of leptin’s effects on hepatic
mitochondria, we wanted to focus on other highly metabolic organs that are good
candidates for leptin-mediated changes in energy expenditure. Skeletal muscle is
another highly metabolic organ (Rolfe and Brand, 1996; Rolfe et al., 1999), which
has been suggested to play a role in the increased energy expenditure associated with
leptin treatment. For this reason we set out to measure mitochondrial respiration in
this organ, specifically respiratory control ratio (RCR) and its components.
RCR is a ratio that represents coupled respiration divided by uncoupled
respiration. Twelve-day leptin treatment of ob/ob mice significantly reduces skeletal
muscle mitochondrial RCR from 3.41 to 2.65 (Figure 30)(p<0.05). This change in
RCR could be due to a decrease in the amount of coupled respiration, an increase in
uncoupled respiration, or both. To explore these possibilities we measured state two,
three, four, and FCCP rates next. Mitochondrial extraction from muscle gives a very
poor yield, and thus five mice were pooled per sample. Each day we recorded from
one sample of ob/ob + pbs mice and one sample of ob/ob + 12 day leptin treated
mice. In order to correct for daily variances in electrode sensitivity - due to freshly
made solutions, membrane permeability, electrode deposits, etc - we divided each of
the recordings by the total amount of respiration recorded for that day. So ob pbs = ob
pbs / (ob pbs + ob lep) ; ob lep = ob lep / (ob pbs + ob lep). This gave us a
“normalized ratio” for each recording that we could compare from day to day.
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Figure 30. Skeletal muscle mitochondria RCR analysis from ob/ob mice
plus/minus leptin. Twelve days of leptin treatment significantly reduces
respiratory control ratio (RCR) in the skeletal muscle of ob/ob mice. n=3 pooled
samples of 5 mice each, and every recording was done in duplicate. = p < 0.05
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State two and four rates give insight into mitochondrial leak, i.e. uncoupled
respiration, and were both altered by leptin. Twelve-day leptin treatment significantly
increased the skeletal muscle state two respiration normalized ratio from 0.45 to 0.55
(Figure 31A)(p<0.01). This initially indicates that mitochondrial leak is increased in
skeletal muscle by leptin, which would explain the decrease in RCR. However, when
looking at state four respiration, we find that it is decreased by twelve-day leptin
treatment from a normalized ratio of 0.55 to 0.45 (Figure 31B)(p<0.01). Further
analysis regarding the meaning of these rates is carried out in the discussion section.
Having explored uncoupled mitochondrial respiration in skeletal muscle, we
next wanted to look at the numerator of RCR, namely coupled respiration. State three
and FCCP rates provide a window into this and were thus recorded next. Twelve-days
of leptin treatment reduced the skeletal muscle state three normalized ratio from 0.62
to 0.38 (Figure 32A)(p<0.01). These results indicate that leptin may be decreasing the
substrate oxidation system, like it does in liver tissue, and could help explain the
changes we saw in RCR. However, though the differences are not yet statistically
significant, further replicates may confirm the trend that FCCP rates are also higher
with leptin treatment (Figure 32B), which would confound our interpretation of the
state 3 rates. The meaning of these results is explored further in the discussion
section.
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Figure 31. Skeletal muscle leak analysis from ob/ob mice
plus/minus leptin. (A) State 2 rates are higher in ob/ob mice treated
with leptin, which initially suggested that a higher proton leak in this group
may be the cause behind the observed changes in the RCR. (B)
However, state 4 rates are lower in the leptin treated group, which make
the interpretation of the state 2 rates more complex. n=3 pooled samples
of 5 mice each, and every recording was done in duplicate. = p < 0.01
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Figure 32. Skeletal muscle substrate oxidation analysis from
ob/ob mice plus/minus leptin. (A) State 3 rates are reduced with leptin
treatment of ob/ob mice. This suggests that leptin may be decreasing
the substrate oxidation system in skeletal muscle, which would be similar
to its effects in the liver. (B) However, though the differences are not yet
statistically significant, further replicates may confirm the trend that
FCCP rates are also higher with leptin treatment, which would confound
our interpretation of the state 3 rates. n=3 pooled samples of 5 mice
each, and every recording was done in duplicate. = p < 0.01
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Leptin Affects Heart Mitochondrial Respiration
Another highly metabolic tissue that makes a good candidate for the site of
leptin-mediated increases in energy expenditure is the heart. We therefore set out to
measure mitochondrial respiration in this organ, again focusing on RCR and its
components. Twelve-day leptin treatment of ob/ob mice lowers RCR in heart muscle
from 3.02 to 2.08 (Figure 33)(p<0.05). Again, this change could be due to a reduction
in coupled respiration, an increase in uncoupled respiration, or both. To gain insight
into which of these possibilities is occurring in vivo, we measured state two, three,
four, and FCCP rates next. Mitochondrial extraction from the heart, though not as
tricky as that from skeletal muscle, also gives a very poor yield, as there is not much
heart tissue in each animal. Thus we again pooled five mice per sample, and recorded
from one group of ob/ob + pbs mice and one group of ob/ob + 12 day leptin treated
mice per day. In order to correct for daily variances in electrode sensitivity, we again
divided each of the recordings by the total amount of respiration recorded for that
day, giving us a “normalized ratio” for each recording.
To look at the uncoupled respiration component of RCR, we recorded state
two and four rates next. Twelve-day leptin treatment significantly decreased heart
mitochondrial state two normalized ratio from 0.57 to 0.43 (Figure 34A)(p<0.05).
State four respiration rates, though not statistically different with the number of
replicated performed, also show a trend to decrease with leptin treatment (Figure
34B). Further interpretation of these rates is carried out in the discussion section.
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Figure 33. Heart mitochondria RCR analysis from ob/ob mice plus/minus
leptin. Twelve days of leptin treatment significantly reduces respiratory control
ratio (RCR) in the heart muscle of ob/ob mice. n=3 pooled samples of 5 mice
each, and every recording was done in duplicate. = p < 0.05
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Figure 34. Heart leak analysis from ob/ob mice plus/minus
leptin. (A) State 2 rates are lower in ob/ob mice treated with leptin,
indicating that proton leak may be lower in the hearts of mice
receiving the hormone. (B) State 4 rates are unchanged with leptin
treatment. n=3 pooled samples of 5 mice each, and every
recording was done in duplicate. = p < 0.05
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Having explored uncoupled mitochondrial respiration in heart muscle, we next
wanted to look at the coupled respiration component of RCR. Twelve-days of leptin
treatment reduced the state three normalized ratio in heart mitochondria from 0.60 to
0.40 (Figure 35A)(p<0.01). These results suggest that leptin may be decreasing the
substrate oxidation system, as it does in liver tissue, and could help explain the
changes seen in RCR. No difference was seen in FCCP rates between leptin treated
and saline treated ob/ob mice (Figure 35B).
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Figure 35. Heart substrate oxidation analysis from ob/ob mice
plus/minus leptin. (A) State 3 rates in heart mitochondria are reduced
with leptin treatment of ob/ob mice. This suggests that leptin may be
decreasing the substrate oxidation system in heart muscle, which would
be similar to its effects in the liver. (B) FCCP rates are unchanged with
leptin treatment. n=3 pooled samples of 5 mice each, and every
recording was done in duplicate. = p < 0.01
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Chapter 4: Discussion
Quantitation of Leptin’s Effects on Thermogenesis and Metabolism
Body weight homeostasis is a fine balance between energy intake and
expenditure (Spiegelman and Flier, 2001), which is innately controlled with an
incredible amount of accuracy (Weigle, 1994). Obesity can only occur in the setting
where energy intake exceeds energy expenditure, i.e. a state of positive energy
balance, for a prolonged period of time. Any intervention that can tip the scale away
from this positive energy balance, through either a reduction in caloric intake or an
increase in energy expenditure, may be useful in combating obesity.
While research on the treatment of obesity has focused heavily on the
importance of food intake, several lines of evidence indicate that alterations of energy
expenditure have a powerful, and perhaps dominant, effect on body weight
(Friedman, 2004). Indeed, energy expenditure, basal metabolic rates and/or adaptive
thermogenesis, are important variables that contribute to human obesity (Bouchard et
al., 1990; Levine et al., 1999; Ravussin, 1995). For example, low energy expenditure
is highly predictive of future weight gain (Ravussin et al., 1988b; Roberts et al.,
1988). Furthermore, weight loss in humans is met with a compensatory decrease in
metabolic rate and increase in appetite, which work in concert to resist changes in
weight (Leibel et al., 1995). These findings suggest that an understanding of the
mechanisms behind changes in energy expenditure is key in combating obesity. Once
such a foundation of knowledge has been established, we can work towards
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pharmacological agents that mimic and augment the increase in resting metabolic rate
induced by exercise. Such agents could be employed to counteract the compensatory
metabolic decreases in response to weight loss discussed above, and may be valuable
tools in our battle against morbid obesity (Friedman, 2004; Harper et al., 2001a;
Lowell and Spiegelman, 2000).
The ob gene product, leptin, is an adipocyte secreted negative feedback
hormone that acts on the hypothalamus (Zhang et al., 1994). This hormone, a key
regulator in body weight homeostasis, is known to decrease energy intake and
increase energy expenditure to tip the scale towards negative energy balance
(Campfield et al., 1995; Halaas et al., 1995; Pelleymounter et al., 1995). Ob/ob
knockout mice lacking the hormone leptin have markedly reduced levels of energy
expenditure, and become obese even when pair fed to littermate controls (Flier,
2004b; Halaas et al., 1995). This and other studies have indicated that leptin’s effects
on caloric intake in treated ob mice accounts for only half of the subsequent weight
loss that is observed (Campfield et al., 1995; Collins et al., 1996; Halaas et al., 1995;
Levin et al., 1996). This is because in addition to reducing caloric intake, leptin
infusion of ob/ob mice increases total energy expenditure, selectively promotes fat
metabolism, and prevents the fall in adaptive thermogenesis that normally occurs with
reduced caloric intake (Doring et al., 1998; Halaas et al., 1997; Hwa et al., 1997;
Kamohara et al., 1997; Mistry et al., 1997; Pelleymounter et al., 1995; Scarpace et al.,
1997; van Dijk et al., 1999).
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After the ingestion of a meal, there is typically an adaptive thermogenesis
response that tries to counteract any excess calories ingested. By adjusting for
changes in physical activity, it has been shown that leptin infusion doubles the
amount of feeding related adaptive thermogenesis by acting on both the amplitude
and duration of it, and decreases postprandial RQ (Ruffin and Nicolaidis, 2000). This
conclusion is consistent with the finding that stimulation of the ventromedial
hypothalamus (VMH), a brain center through which leptin exerts some of its
catabolic effects, increases metabolism and decreases RQ (Ruffin and Nicolaidis,
1999), while lesions in this area cause obesity (Elmquist et al., 1999a). Therefore, a
significant portion of leptin-mediated weight loss can be attributed to an increase in
energy expenditure, some of which, but not all, being attributable to adaptive
thermogenesis.
Much progress has been made in understanding leptin’s role in inducing
satiety (Emond et al., 1999; Schwartz et al., 2000a) and the neural networks through
which it triggers a rise in energy expenditure (Bachman et al., 2002; Elias et al.,
1998). However, little remains known about the downstream effector mechanisms by
which the hormone increases energy expenditure, specifically adaptive thermogenesis
(Spiegelman and Flier, 2001). In this report we tease apart the mechanisms through
which leptin causes weight loss, demonstrate its effects on the mitochondrial structure
and metabolism of three energy demanding organs, and delve into the underlying
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kinetic and proteomic modifications to develop a deeper understanding of the
observed changes.
Our results demonstrate that leptin-mediated weight loss is attributable to
three major changes brought about by the hormone, namely its induction of satiety
(Figure 9B, arrow 1), its correction of body temperature (arrow 2), and its activation
of increases in energy expenditure and basal metabolic rate (arrow 3). The
mechanisms underlying the anorexigenic effects of leptin were discussed earlier, and
its correction of body temperature may be due to the hormone’s stimulation of
sympathetic activity in brown fat (Collins et al., 1996; Haynes et al., 1997) and
increase of UCP-1 mRNA and protein levels (Cusin et al., 1998; Satoh, 1998;
Scarpace et al., 1997). Thus, for the remainder of our investigation we chose to
explore the least understood of the changes brought about by leptin, i.e. the increase
in energy expenditure and basal metabolic rate.
Lepin-Mediated Changes in Liver Metabolism
The liver is a major player in lipid homeostasis, and comprises a significant
fraction of standard metabolic rate (Porter and Brand, 1993). It is also a known
contributor to the catabolic effects of leptin (Cohen et al., 2002), and thus makes a
good candidate for leptin-mediated increases in metabolic rate and adaptive
thermogenesis. Our study into the livers of leptin deficient ob/ob mice showed that
they are extremely steatotic, a finding that is corrected by twelve-day leptin treatment
of the animals. Measurements of triglyceride levels in the livers of animals housed at
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22oC or 30oC were able to show that the correction of steatosis by leptin is due to
both normalization of body temperature by the hormone, and leptin-induced increases
in energy expenditure and basal metabolic rate (Figure 10). These data suggest that
part of the weight loss associated with leptin treatment is occurring in the liver. To
study the leptin-induced increase in energy expenditure and basal metabolic rate in
further detail, we wanted to take a closer look at hepatic metabolism during leptin
treatment.
Whole cell oxygen consumption recordings from freshly isolated primary
hepatocytes using a Clarke electrode can be useful in identifying changes in the
metabolic state of the liver (Brand et al., 1993; Harper and Brand, 1993; Porter and
Brand, 1995; Porter, 2001; Schumacker et al., 1993), and were thus employed in our
study. Significant differences were found in the basal metabolic rate, uncoupled
respiration (i.e. leak), and non-mitochondrial respiration of primary hepatocytes
isolated from saline treated and leptin treated ob/ob mice (Figure 11). However,
contrary to what we were expecting, isolated primary hepatocytes from 12-day leptin
infused mice had lower basal metabolic rates and non-mitochondrial respiration than
those from saline infused mice (Figure 11A and C). The respiratory leak in 12-day
leptin infused ob/ob mice was lower than of saline treated mice (Figure 11B), which
is consistent with what has been reported previously (Melia et al., 1999). These data
show that while the liver plays a definitive role in the change in energy expenditure
and basal metabolic rate brought about by leptin, it may not be an effector organ for
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the increase in adaptive thermogenesis as we originally thought. To study these
leptin-induced changes in hepatocyte energy expenditure in further detail, we went on
to look at liver mitochondrial metabolism.
Measurement of the components of mitochondrial respiration has proven to be
useful in identifying the changes underlying differences in metabolic rates (Brand et
al., 1999; Brand et al., 1994; Brown et al., 1990; St-Pierre et al., 2003). Modular
kinetic analysis conducted alongside such measurements allows one to gain further
insight into the kinetic properties mitochondrial leak, substrate oxidation, and the
phosphorylation system (Brand et al., 1993; Hafner et al., 1990; Porter and Brand,
1995). To further investigate the possibility of mitochondrial metabolic changes in the
liver brought about by leptin, we both measured the different components of hepatic
mitochondrial respiration, and conducted modular kinetic analysis.
Our results demonstrate that leptin increases the respiratory control ratio
(RCR) of liver mitochondria in ob/ob mice (Figure 12). This indicates that hepatic
mitochondrial respiration is more coupled in mice receiving leptin, a phenomenon
that is the opposite of what we expected to see. State two and four rates decrease with
leptin treatment as well (Figure 13), which one may interpret as an indication that
mitochondrial leak is decreasing. If this were the case, the decreased leak with leptin
treatment would explain the increased RCR, as the leak rate is the denominator of the
RCR ratio. However, we find that FCCP rates also decrease with leptin treatment
(Figure 14), which indicates that the hormone is suppressing the substrate oxidation
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system. A decrease in substrate oxidation would cause a subsequent decrease in the
proton gradient across the inner mitochondrial membrane, which would reduce the
electro-chemical driving force for proton leak. Similarly, a decrease in proton leak
would cause a subsequent increase in the proton gradient across the inner
mitochondrial membrane, which would increase the resistance against which the
substrate oxidation system has to pump protons. These findings raise the proverbial
“chicken or egg” question, i.e. is the decreased proton leak leading to a decrease in
the substrate oxidation system, or vice versa. To settle this issue we turned to modular
kinetic analysis, which measures both leak and substrate oxidation as a function of
mitochondrial inner membrane potential, and thus allows us to measure each rate
without the confounding effects of the other.
In modular kinetic analysis, one dissipates the mitochondrial inner membrane
potential in a stepwise fashion and concurrently uses different assortments of
mitochondrial inhibitors to measure the kinetics of the substrate oxidation system,
phosphorylation system, and proton leak (Brand et al., 1993; Hafner et al., 1990;
Porter and Brand, 1995). Conducting these measurements in ob/ob and wild-type
mice treated with both leptin and pbs revealed that the leptin-mediated changes in
liver mitochondrial metabolism are due to the hormones effect on the substrate
oxidation system (Figure 17). Leak and phosphorylation system kinetics were not
altered by lepin (Figure 18), and the changes in leak rates seen earlier were secondary
to the effects of the substrate oxidation system on the mitochondrial inner membrane
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potential. The reason differences in leak rates emerged is because leak in ob/ob + pbs
mice is more sensitive to changes in inner membrane potential than it is in ob/ob +
lep, wt + pbs, or wt + lep mice. This can been seen on in figure 18A, where at higher
membrane potentials, the leak increases much more in the ob/ob + pbs mice than it
does in any of the other groups.
In light of these observations, one wonders if the observed change in substrate
oxidation kinetics is a secondary response to the hepatic steatosis exhibited by ob/ob
mice, attempting to increase oxidative phosphorylation rates in the face of
compromised fatty acid oxidation. Induction of hypo-leptinemia in wt mice is an
innovative way to distinguish between the direct effects of leptin, and those that are
secondary to its correction of hepatic steatosis (Montez et al., 2005). Employing this
method, we show that state two and four respiration rates aren’t affected in
hypoleptinemic wt mice (Figure 20). This suggests that leptin levels don’t influence
mitochondrial leak, a finding that is consistent with what was seen in ob/ob mice
using modular kinetic analysis. Furthermore, FCCP rates are higher in
hypoleptinemic mice (Figre 21), indicating that leptin levels affect the substrate
oxidation system, which is also consistent with findings in ob/ob mice. Since the
metabolic changes during leptin deficiency and restoration are the same in the
presence or absence of hepatic steatosis, we can conclude that leptin’s control over
the hepatic mitochondrial substrate oxidation system is independent of its effects on
hepatic fat stores.
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Leptin’s Influence Over Hepatic Mitochondrial Structure
There is a positive correlation between the metabolic activity of a tissue and
the morphologic features of the mitochondria in that tissue - such as size, volume
density, and cristae structure (Ghadially, 1988). Furthermore, studies of adaptive
thermogenesis have shown oxygen consumption to be correlated with cristae length
and density (Martin et al., 1999; Rodriguez-Cuenca et al., 2002). Having observed
changes in liver mitochondrial metabolism with leptin treatment, we wanted to
measure mitochondria morphology to see if it was affected as well.
Our electron micrographic investigation of ob/ob livers reveals that leptin
treatment of these mice causes a change in mitochondrial appearance and cristae
structure (Figures 22-24). Though leptin does not change individual mitochondrion
size, it significantly decreases the numerical and volume density of hepatic
mitochondria in ob/ob mice (Figure 25). We also know from modular kinetic analysis
that the mitochondria from leptin treated ob/ob mice have a suppressed substrate
oxidation system. This reduction in mitochondrial volume alongside the suppression
of the substrate oxidation system, could explain the previously discussed decrease in
hepatocyte basal metabolic rate brought about by the hormone. Therefore, the
structural data give an indication that both volumetric and metabolic differences in
these hepatic mitochondria may be contributing to the changes observed in the liver.
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Leptin’s Influence Over the Hepatic Mitochondrial Mileu
Leptin has an extensive range of effects that take shape through its influence
over numerous molecular pathways (Flier, 2004b; Friedman, 1998). To circumvent
the difficulty in identifying which of these pathways exert leptin’s influence over
substrate oxidation, we purified mitochondria and measured their protein content in
ob/ob and wild-type mice after 12 days of treatment with either leptin or saline.
Interestingly, we found that three components of the electron transport chain were
significantly increased in abundance during leptin deficiency, and decreased during
leptin infusion (Figure 26). These were cytochrome c oxidase subunit IV, cytochrome
c oxidase subunit VIa, and mitochondrial NADH dehydrogenase. Leptin’s influence
over the protein levels of these mitochondrial respiratory chain components may be
the mechanism by which it causes the observed differences in substrate oxidation
described earlier.
Also interesting to note were the changes in protein levels of the long chain
fatty acid elongase ELOVL5, which were drastically increased in abundance in ob/ob
mice as compared to wild-type littermates, and were significantly decreased with
leptin treatment of these ob/obs (Figure 26). The induction of this enzyme has been
shown to cause massive hepatic accumulation of mono-unsaturated fatty acids (Wang
et al., 2006). Perhaps the low level of this enzyme in leptin deficiency is underlying
the hepatic steatosis observed in ob/ob animals, and its increase with leptin infusion
leads to the correction of this state.
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Changes in mitochondrial lipid levels can affect mitochondrial function, and
more importantly changes in mitochondrial metabolism can influence the lipid
composition of the organelle (Ball and Joel, 1962; Paradies et al., 1999; Paradies and
Ruggiero, 1991; Senault et al., 1990). Furthermore, in both diabetes and insulin
treatment of the disorder, there are changes induced in the lipid/phospholipid
composition of mitochondria (Patel and Katyare, 2006). Having found that leptin
affects the mitochondrial substrate oxidation system in a way to decrease
mitochondrial metabolism, we wanted to see if we could identify corresponding
changes in mitochondrial lipids induced by the hormone. Using mass spectrometry,
we were able to show that cardiolipin levels are significantly higher in ob/ob mice
than in wild-type mice, a difference that was diminished by leptin treatment (Figure
27). Interestingly, cardiolipin interacts with the mitochondrial respiratory chain and
can change the efficiency of oxidative phosphorylation (Gohil et al., 2004; Hatch and
McClarty, 1998; Hoch, 1992; Hoch, 1998; Koshkin and Greenberg, 2000). Perhaps
changes in cardiolipin are relevant to the lepin-induced changes in mitochondrial
metabolism.
In addition to affecting the lipid composition of mitochondria, changes in
mitochondrial metabolism can influence free-radical production in the organelle
(Andrews et al., 2005). Studies have documented increased oxidative stress in obese
individuals and have noted its impact on the metabolic syndrome (Furukawa et al.,
2004; Keaney et al., 2003). Indeed, many studies argue that oxidative stress and the
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signaling pathways it activates are mediators of insulin resistence and beta cell
dysfunction in type 2 diabetes (Evans et al., 2002; Evans et al., 2003; Kelley et al.,
2002; Schrauwen and Hesselink, 2004). Some go on to link central obesity as a cause
of the oxidative stress that subsequently leads to atherosclerosis, endothelial
dysfunction, and beta cell failure (Bakker et al., 2000; Perticone et al., 2001).
The mitochondrial electron transport chain is the main producer of reactive
oxygen species (ROS) in most cells (St-Pierre et al., 2006). Since we found leptin to
have metabolic, proteomic, and lipidomic effects on the electron transport chain of
hepatocytes, we wanted to see if this caused a subsequent change in ROS production.
To take a deeper look at the effects of leptin on ROS levels, we measured oxidated
fatty acid (oxFA) levels from the livers of wild-type + saline, wild-type + leptin,
ob/ob + saline, ob/ob + 2 days leptin, and ob/ob + 12 days leptin mice. Our studies
found a trend of increased oxFA with leptin treatment (Figures 28 and 29). While
these trends are not statistically significant as they stand, our collaborator recording
the oxFA levels is confident that they will be with further replicates. Such data would
fit in well with previous findings that leptin induces oxidative stress in a variety of
organisms (Beltowski et al., 2003; Bouloumie et al., 1999; Yamagishi et al., 2001).
Lepin’s Effects on Skeletal Muscle and Heart Metabolism
Calorimetric studies have shown leptin to increase whole body oxygen
consumption in ob/ob mice (Campfield et al., 1995; Halaas et al., 1997; Halaas et al.,
1995; Pelleymounter et al., 1995). However, our measurements show that the

116

hormone decreases basal metabolic rate in hepatocytes and inhibits the substrate
oxidation system in hepatic mitochondria. In order for both observations to be correct,
there must be other organs in which leptin increases energy expenditure. The heart
and skeletal muscle comprise a significant fraction of standard metabolic rate (Rolfe
and Brand, 1996; Rolfe et al., 1999), and thus make good candidates for other tissues
upon which leptin may be exerting its metabolic effects. To measure the effects of
leptin on these tissues we measured the different components of mitochondrial
respiration from ob/ob mice treated with either leptin or saline for twelve days.
Our results show that, opposite to its effects in the liver, leptin significantly
decreases respiratory control ratio (RCR) in skeletal muscle (Figure 30). To explore
the cause(s) behind this change, we took a further look at mitochondrial leak and
coupled respiration, the two components of RCR. State two rates were found to be
higher with leptin treatment (Figure 31A), which initially indicated that mitochondrial
leak might be increased in animals receiving the hormone. This could help explain the
lower RCR, as mitochondrial leak is the denominator in the RCR ratio. However, we
also observed that state four respiration is decreased with leptin treatment (Figure
31B), which would suggest that mitochondrial leak is decreased. The conflicting state
two and four findings confound our analysis of uncoupled respiration and do not
allow us to come up with a definitive conclusion regarding changes to mitochondrial
leak. To resolve this issue, one would have to do modular kinetic analysis using a
TPMP electrode.
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A similar situation arises with state three and FCCP rates in skeletal muscle
mitochondria. Leptin treatment significantly lowers state three rates (Figure 32A),
which indicates that the hormone may decrease coupled respiration. This would also
explain the changes to RCR, as coupled respiration is the numerator in the RCR ratio.
However, though they are not statistically significant as they stand, FCCP rates show
a nearly significant trend of increasing with leptin treatment (Figure 32B). Perhaps
further replicates of this recording would bring the trend to significance, in which
case there would be a conflict regarding the interpretation of coupled respiration.
Once again, modular kinetic analysis using a TPMP electrode could be employed to
resolve the issue.
Turning our attention to heart mitochondria, we find that twelve days of leptin
treatment also decreases the RCR in this tissue (Figure 33). To explore the cause(s)
behind this change, we again took a further look at mitochondrial leak and coupled
respiration. State two and four rates are reduced with leptin treatment (Figure 34),
which indicates that mitochondrial leak may be decreased in the hearts of mice
receiving the hormone. At the same time state three rates are decreased with leptin
treatment as well (Figure 35), which suggests that substrate oxidation may be reduced
in the hearts of leptin treated ob/ob animals. This raises the proverbial chicken and
egg question once more. Is the decreased leak causing a buildup of the proton
gradient, and thus slowing substrate oxidation rates by forcing the mitochondrial
respiratory chain to pump against a higher eletro-checmical force? On the other hand,
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are decreased substrate oxidation rates resulting in a smaller mitochondrial inner
membrane proton gradient, causing subsequent decreases in proton leak rates? To
answer these questions, one could conduct modular kinetic analysis on isolated heart
mitochondria.
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Conclusion
The primary goal of the work described here was to gain a better
understanding of the cellular and molecular mechanisms underlying leptin’s
metabolic effects. The experiments in this thesis start off by identifying the three
different ways in which leptin causes weight loss, namely the induction of satiety, the
normalization of body temperature, and the increase of energy expenditure and basal
metabolic rate. They then go on to take an in depth look at the liver, skeletal muscle
and heart, which we felt were three strong candidate organs for involvement in the
leptin mediated increase of energy expenditure.
We report that leptin treatment of ob/ob mice reduces the basal metabolic rate,
uncoupled respiration (i.e. leak), and non-mitochondrial respiration of primary
hepatocytes. By recording the components of mitochondrial respiration and
conducting modular kinetic analysis, we show that leptin treatment of ob/ob mice
decreases the substrate oxidation system in the liver. In vivo withdrawal studies show
that these changes are directly caused by leptin, and are not downstream of the
hormone’s correction of hepatic steatosis. Furthermore, electron microscopy and
morphometry studies reveal that in addition to causing metabolic changes in
mitochondria, leptin treatment changes mitochondrial structure, size, and volume
density in the liver. Thus we are able to provide both a metabolic and structural basis
for our observed effects of leptin on hepatocytes.
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We next wanted to see if we could find the proteomic and lipidomic changes
underlying the metabolic and structural changes discussed above. Proteomic analysis
using iTRAQ tandem mass spectrometry quantification revealed that leptin-mediated
changes in three components of the mitochondrial respiratory chain could account for
the aforementioned metabolic effects of leptin in the liver. It also showed that drastic
changes in levels of the enzyme ELOVL5 might be responsible for the hepatic
steatosis exhibited with leptin deficiency, and for its correction with leptin treatment.
Furthermore, mass spectrometry showed differences in mitochondrial cardiolipin
levels that are associated with the observed leptin-mediated changes in the liver.
Finally, our measurements of oxidated fatty acids show a trend that leptin may be
altering the levels of reactive oxygen species in hepatic mitochondria. Thus we are
able to provide a proteomic and lipidomic basis for our observed effects of leptin on
liver mitochondrial metabolism and hepatic steatosis, and show additional effects of
the hormone on the mitochondrial milieu.
Having completed a thorough investigation into leptin-mediated changes in
the liver, we moved on to the other two candidate organs, the heart and skeletal
muscle. Our findings show that the respiratory control ratio (RCR) is reduced in
mitochondria isolated from both the heart and skeletal muscle of mice treated with
leptin for 12 days. In skeletal muscle, state two and four recordings are somewhat
conflicting about leptin-mediated changes in mitochondrial leak, and state three and
FCCP rates are somewhat conflicting about changes in coupled respiration. The
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mitochondrial rates paint a clearer picture in the heart, showing that both leak and
coupled respiration are decreased with leptin treatment. However, it is likely that
there is interplay between these rates, and one cannot say which is influencing the
other. To resolve both this issue and the conflicts in interpretation of skeletal muscle
rates, one needs to conduct modular kinetic analysis. Thus, our results show that
leptin clearly modulates mitochondrial respiration in the heart and skeletal muscle,
though we cannot yet say exactly how it does so.
In conclusion, our analysis of the liver shows that leptin decreases
mitochondrial substrate oxidation and volume density, leading to a resultant decrease
in hepatocyte basal metabolic rate. It does so by changing levels of three proteins in
the mitochondrial respiratory chain. These effects are a direct result of leptin and not
secondary to its correction of hepatic steatosis, which is likely occurring through its
influence on the fatty acid elongase ELOVL5. We also clearly show that skeletal
muscle and heart metabolism are changed with leptin treatment, and lay the
foundation for future work on these tissues. These observations advance our
understanding of the catabolic effects of leptin, and bring us one step closer to
coming up with potential therapeutic treatments for obesity that approach the problem
from a completely new angle.
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